U.S. patent application number 15/744198 was filed with the patent office on 2018-07-19 for microdroplet based bioassay platform.
The applicant listed for this patent is Northeastern University. Invention is credited to Tania KONRY, Pooja SABHACHANDANI, Saheli SARKAR.
Application Number | 20180203005 15/744198 |
Document ID | / |
Family ID | 57757652 |
Filed Date | 2018-07-19 |
United States Patent
Application |
20180203005 |
Kind Code |
A1 |
KONRY; Tania ; et
al. |
July 19, 2018 |
Microdroplet Based Bioassay Platform
Abstract
Platform technology involving aqueous microdroplet reaction
vessels created, arrayed, and characterized by imaging microscopy
in a microfluidic device are applied to a wide variety of bioassays
involving the detection and phenotypic characterization of single
cells. The bioassays include the rapid and automated detection of
microbial pathogens and their antibiotic sensitivity from patient
samples as well as the characterization of immune responses using a
patient's own cells, including the killing of tumor cells.
Inventors: |
KONRY; Tania; (Boston,
MA) ; SABHACHANDANI; Pooja; (Boston, MA) ;
SARKAR; Saheli; (Boston, MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Northeastern University |
Boston |
MA |
US |
|
|
Family ID: |
57757652 |
Appl. No.: |
15/744198 |
Filed: |
July 15, 2016 |
PCT Filed: |
July 15, 2016 |
PCT NO: |
PCT/US2016/042677 |
371 Date: |
January 12, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62192958 |
Jul 15, 2015 |
|
|
|
62291933 |
Feb 5, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
G01N 33/533 20130101;
B01L 3/502761 20130101; G01N 35/08 20130101; G01N 33/6863 20130101;
G01N 33/5432 20130101; G01N 33/57492 20130101; B01L 3/0241
20130101; B01L 3/502784 20130101; G01N 33/56911 20130101; G01N
33/56966 20130101; B01F 13/0071 20130101; B01L 2200/0668 20130101;
G01N 33/54346 20130101 |
International
Class: |
G01N 33/543 20060101
G01N033/543; G01N 35/08 20060101 G01N035/08; G01N 33/569 20060101
G01N033/569; G01N 33/574 20060101 G01N033/574; G01N 33/68 20060101
G01N033/68; B01L 3/00 20060101 B01L003/00; B01L 3/02 20060101
B01L003/02; G01N 33/533 20060101 G01N033/533 |
Claims
1. A method of detecting bacterial cells, the method comprising the
steps of: (a) providing a microfluidic device capable of forming
aqueous microdroplets in oil, the device comprising a translucent
microdroplet array chamber, and providing a fluorescence imaging
microscope; (b) preparing a plurality of aqueous microdroplets in
oil using the microfluidic device, each microdroplet comprising a
sample containing or suspected of containing one or more bacterial
cells, one or more microbeads conjugated with a capture antibody
capable of specifically binding a selected type of bacterial cell
at a first epitope, and a fluorescently labeled detection antibody
capable of specifically binding the selected type of bacterial cell
at a second epitope; (c) directing the plurality of aqueous
microdroplets into the microdroplet array chamber; (d) obtaining a
fluorescence image of the microdroplet array chamber using the
fluorescence imaging microscope; and (e) measuring fluorescence
emission from the labeled detection antibody in images of the
microbeads, whereby the presence of the selected type of bacterial
cell in the sample is detected when fluorescence emission from the
labeled detection antibody overlaps with an image of one or more of
said microbeads.
2. The method of claim 1 which is carried out in multiplex format
using two or more types of microbeads, each type of microbeads
conjugated with a capture antibody that specifically binds a
different type of bacterial cell, and using two or more types of
distinctly fluorescent labeled detection antibodies, and wherein
two or more types of bacteria are detected simultaneously.
3. The method of claim 1, wherein one or more reagents are added to
the aqueous microdroplets after their formation using a droplet
merging junction.
4. The method of claim 1, wherein aqueous microdroplets are sorted
and routed to a selected fluidic pathway, chamber, or off-device
location, according to fluorescence detected in the aqueous
microdroplets.
5. The method of claim 1, further comprising analyzing a phenotype
of one or more bacterial cells in an aqueous microdroplet.
6. The method of claim 5, wherein the phenotype is antibiotic
sensitivity, and wherein the aqueous microdroplets comprise an
antibiotic suspected of killing or hindering growth of the selected
type of bacteria, and bacterial growth and/or viability in the
microdroplet is assessed.
7. The method of claim 1, wherein the sample is a patient sample
selected from the group consisting of urine, blood, serum, plasma,
sputum, or a lavage fluid.
8. The method of claim 7, wherein the patient sample is urine, and
a urinary tract infection is diagnosed.
9. The method of claim 7, wherein the patient sample is blood,
serum, or plasma, and sepsis is diagnosed.
10. The method of claim 7, wherein the patient sample is sputum or
a lavage fluid, and a pulmonary or gastric infection is
diagnosed.
11. The method of claim 1, wherein the aqueous microdroplets
further comprise one or more additional types of microbeads, each
type conjugated with a capture antibody capable of specifically
binding an analyte present in or suspected of being present in the
sample, and one or more distinctly fluorescently labeled detection
antibodies capable of specifically binding the analyte.
12. A method of analyzing a cell phenotype, the method comprising
the steps of: (a) providing a microfluidic device capable of
forming aqueous microdroplets in oil, the device comprising a
translucent microdroplet array chamber, and providing an imaging
microscope; (b) preparing a plurality of aqueous microdroplets in
oil using the microfluidic device, each microdroplet comprising a
sample containing or suspected of containing one or more cells and
one or more reagents for analyzing a phenotype of said cells; (c)
directing the plurality of aqueous microdroplets into the
microdroplet array chamber; (d) obtaining an image of the
microdroplet array chamber using the imaging microscope; and (e)
measuring an optical signal from said reagent, whereby information
regarding the phenotype of said cells is obtained.
13. The method of claim 12, wherein the phenotype is cytokine
secretion by the cells, and the reagents comprise a microbead
conjugated capture antibody and a fluorescent labeled detection
antibody, wherein both antibodies specifically bind to said
cytokine.
14. The method of claim 12, wherein the phenotype is cell
viability, and the reagents comprise a fluorescent indicator of
live vs. dead cells.
15. The method of claim 12, wherein the phenotype is susceptibility
to an antitumor agent, the cells comprise tumor cells, and the
reagents comprise the antitumor agent.
16. The method of claim 12, wherein the phenotype is activation of
an immune response, the cells comprise T lymphocytes, and the
reagents comprise antigen presenting cells.
17. The method of claim 12, wherein the phenotype is the presence
of a biomarker, and the reagents comprise a microbead conjugated
capture antibody and a fluorescent labeled detection antibody,
wherein the capture antibody specifically binds to an epitope on a
selected cell type and the detection antibody specifically binds to
said biomarker.
18. The method of claim 12, wherein the phenotype is the action of
a pharmaceutical agent on the cells, and the reagents comprise an
optical indicator of an effect of the pharmaceutical agent on the
cells.
19. The method of claim 12, wherein one or more additional reagents
are added to the aqueous microdroplets after their formation using
a droplet merging junction.
20. The method of claim 12, wherein aqueous microdroplets are
sorted and routed to a selected fluidic pathway, chamber, or off
device location, according to an optical signal detected in the
aqueous microdroplets.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority of U.S. Provisional
Application No. 62/192,958 filed 15 Jul. 2015 and entitled
"Functional Phenotyping of Cells in Droplet Based Platforms" and of
U.S. Provisional Application No. 62/291,933, filed 5 Feb. 2016 and
entitled "Platforms for Microbial Detection and Phenotypic Drug
Analysis". The whole of these provisional applications is hereby
incorporated by reference.
BACKGROUND
[0002] The rapid emergence of antibiotic resistance, and decline in
discovery of new antibiotics, has created a significant gap in the
effective management of microbial infections. Additionally,
persistent use of antibiotics in agriculture has further increased
antibiotic resistant bacteria strains, thus making antibiotic
resistant microbial infections an acute public health concern.
According to the WHO global surveillance report for antimicrobial
resistance, very high rates of resistance have been observed in
common bacterial strains such as Escherichia coli, Klebsiella
pneumonia and Staphylococcus aureus
(apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=).
[0003] E. coli related urinary tract infections (UTIs) are among
the most frequently encountered bacterial infections in the United
States (1,2) with an annual incidence of over 8 million. Infection
may involve both lower (bladder, cystitis) and upper urinary tract
(kidney, pyelonephritis) and lead to significant morbidity,
including permanent kidney damage (chronic pyelonephritis) or life
threatening bacterial sepsis. The cumulative morbidity is profound
with over 100,000 hospitalizations per annum. (3)
[0004] Appropriate treatment of UTI is critical for optimal outcome
and requires use of agents that are active against the infecting
pathogen. In the outpatient setting, patients are often prescribed
empiric antibiotic therapy as susceptibility patterns of
uropathogens have, until recently, been generally predictable. In
hospitalized patients, empiric therapy is given for 48-72 hours
until traditional culture results and susceptibility data are
available. However, the rapid emergence of antibiotic resistance in
recent years presents a significant challenge for UTI
management.(4-8) In particular, carbapenem-resistant and
extended-spectrum .beta.-lactamase producing Enterobacteriaceae are
an immediate public health threats, as they express resistance to
commonly used empiric antimicrobial regimens. (9-11) Pathogens
amongst the ESKAPE group are predicted to become resistant to
currently available antibiotics within the next decade. Alarmingly,
these are amongst the most common agents of UTI seen in
hospitalized patients.
[0005] Initiation of active, appropriate antimicrobial patient
therapy is ultimately dependent upon turnaround time of infection
diagnostic methods. (12) Historically, this testing has relied on
routine culture to isolate organisms; biochemical tests for
bacterial identification; and culture based antibiotic
susceptibility testing (AST). (13) However, using traditional
technology, susceptibility results are generally not available for
48-72 hours. This means that for the first three days of suspected
infection, therapy is largely unguided. Therefore, the ability to
shrink this window by rapidly performing AST for bacterial
pathogens is urgently needed. Rapid AST will also decrease
emergence of resistance by allowing targeted (antibiotic
de-escalation) or discontinuation of therapy if bacterial infection
is ruled out (14,15).
[0006] New technologies have been applied to address this problem
(16). For example, MALDI-TOF mass spectrometry (MS) and nucleic
acid amplification tests (NAATs) are beginning to transform the
clinical microbiology laboratory. These newer platforms offer
several benefits over traditional culture methods; however, they
also have significant limitations. MS is generally rapid and can
identify a large database of bacteria. However, lengthy culture
pre-amplification is still required, since analysis can only be
performed on isolated bacterial colonies. (17) Also, MS-based AST
only marginally decreases the time needed to identify organisms and
does not address the need for rapid AST. Lastly, MS equipment is
expensive ($200,000-300,000), bulky, complex to operate, and
requires regular maintenance. (16) Therefore, MS systems must be
placed in a centralized laboratory, away from the site of patient
care, further delaying access to diagnostics.
[0007] Alternatively, NAATs have the capability to identify
specific organisms or resistance genes directly from a clinical
sample within two hours, including sample preparation. (18-21)
However, they fall short in their ability to yield a comprehensive
resistance profile. Specifically, resistance mechanisms are often
multifactorial. Therefore, even highly multiplexed NAATs cannot
accurately predict phenotypic susceptibility. (22) For example,
resistance to a carbapenem in Gram negative bacilli (GNB) may
reflect contributions from multiple .beta.-lactamases, porins, and
efflux pumps. Indeed, a GNB producing the New Delhi
metallo-.beta.-lactamase 1 (NDM-1) enzyme may carry up to eight
plasmids (5) together encoding scores of resistance elements that
may interact in unexpected ways. (23) Therefore, the Clinical and
Laboratory Standards Institute (CLSI) now recommends using
carbapenem MIC as the sole criterion for assessing susceptibility,
as the mere presence or absence of a CRE genetic element alone does
not predict phenotypic response.
[0008] Heterogeneity in single cell responses arises from intrinsic
stochasticity in both transcription and translation, thereby
leading to significant variability in quantitative levels of mRNA
and protein within cell populations. This results in biological
noise, which can be further enhanced by minor differences in
environmental stimuli, variations in cell state and polyfunctional
responses. This heterogeneity is an essential characteristic of
cellular systems and must be assessed by analyzing individual cell
behavior. Furthermore, the dynamic nature of biological processes
occurs at varying time scales, requiring continuous real-time
evaluation of single cell outcomes. This is particularly evident in
analysis of immune responses, which involve a variety of cell
types.
[0009] Currently, flow cytometry is the most useful technique for
single cell analysis, due to its high-throughput and multiplexing
capability. However, it cannot provide time-varying spatiotemporal
resolution of signaling dynamics in the same cell. Other single
cell analysis techniques include laser scanning cytometry,
capillary electrophoresis and laser capture microdissection. Many
of these techniques suffer from limitations of throughput and
complicated operation.
[0010] Microfluidic single cell analysis tools have emerged as a
powerful alternative to conventional cell culture techniques with
respect to throughput, multiplexing, sensitivity, and robust
control of cellular microenvironment. Single cells have been
captured by valve-based methods (67), dielectrophoretic mechanisms
(68,69), and optical tweezers (70). However, active mechanisms such
as dielectric forces can negatively impact cell viability;
additionally, the throughput achieved with these methods is
generally low. Microwells utilize passive gravity-based methods to
allow single cell sedimentation followed by stimulation of cells
(71, 72). However, non-adherent cells could potentially be lost
from their holding sites over time with this technology. Another
commonly implemented method relies on manipulating fluid flow or
employing hydrodynamic guiding features to direct cells towards
traps, thus allowing cells to be sequestered in variously shaped
docking structures (73-76). Hydrodynamic arrays have been
extensively investigated to achieve optimal capture efficiency and
single cell compartmentalization by assessing various trap
structure, position and distance (77-80). However, a common
limiting feature of most of these microfluidic approaches is the
lack of isolation of a cell from its neighbors, leaving room for
paracrine effects. Thus, there remains a need for new methods that
allow cell function and cell-cell interactions to be analyzed in
isolation.
SUMMARY OF THE INVENTION
[0011] The invention provides a fast, highly sensitive,
direct-from-patient, microfluidic droplet-based bioassay platform
that offers single cell based analysis for efficient monitoring of
bacterial infection and cell function, as well as for high
throughput testing of the susceptibility of single cells to
antibiotics and other pharmaceutical agents. The methods and
devices provided can be used to monitor bacteria and perform
antibiotic susceptibility testing for urinary tract infection
directly from patient samples with no or minimal pre-processing
steps.
[0012] The bioassay platform is based on analysis of an array of
single droplets using a microfluidics device coupled with a
fluorescence microscopy imaging system. Cells are encapsulated in
aqueous microdroplets suspended in an oil medium and directed,
sorted, and arranged by the microfluidic device for analysis, which
may include identification and quantification of the cells as well
as characterization of cell phenotype, such as function, gene
expression, presence or absence of biomarkers, or susceptibility to
antiibiotics or other drugs. Various reagents for the analysis can
be added to the droplets at formation or by later merger of
droplets. Such reagents include antibody-conjugated microspheres,
fluorescent detection antibodies, cell viability indicators,
antibiotics or drugs, and other cells for cell-cell interaction
studies. The analysis of single droplets provides high sensitivity
and short reaction times. A further advantage is the use of an on
chip docking array, where up to hundreds or thousands of
microdroplets can be maintained stably for long-term culture, such
as to assess time-variant growth dynamics of encapsulated bacteria
at single cell resolution or to study T-cell mediated killing of
tumor cells, for example. Tracking individual cells such as
bacteria over time can provide critical information on cellular
heterogeneity based on characteristics such as cell division,
density, morphology and antibiotic resistance.
[0013] The invention provides diagnostic methods for detecting and
quantifying bacterial pathogens, including the most prevalent and
antibiotic-resistant pathogens, without the need for culture or
pre-amplification, and provide automated phenotypic analysis,
including antibiotic susceptibility, within a few hours, such as 3
hours, of sample acquisition. Bacterial cells present in urine
samples are co-encapsulated with various antibiotics at 1-4 cells
in picoliter-volume droplets for determination of susceptibility
within 1 hour by standard fluorescence microscopy imaging. The
original patient sample concentration can be as low as 50000
CFU/mL. Furthermore, urine also can be analyzed to assess the state
of inflammation in the patient by enumeration of white blood cells
and cytokines, which aids in distinguishing true infection from
sample contamination. IL-6 and IL-8 are produced by infected
urothelial cells based on recognition of pathogen associated
molecular patterns (24-27), and therefore provide a measure of
inflammatory state, even in highly immunocompromised patients who
do not mount a significant WBC response. (28,29)
[0014] Furthermore, the present microfluidics-based technology can
be deployed with inexpensive portable instrumentation and
disposables. The portability and low cost of consumables should
permit distribution to sites of patient care in hospitals, primary
care, and resource-limited settings, thereby accelerating
personalized therapy and improving patient outcomes. The same
qualities also make the technology ideal to identify infected
patients efficiently for clinical trial enrollment.
[0015] The invention can be summarized further by the following
list of embodiments: [0016] 1. A method of detecting bacterial
cells, the method comprising the steps of:
[0017] (a) providing a microfluidic device capable of forming
aqueous microdroplets in oil, the device comprising a translucent
microdroplet array chamber, and providing a fluorescence imaging
microscope;
[0018] (b) preparing a plurality of aqueous microdroplets in oil
using the microfluidic device, each microdroplet comprising a
sample containing or suspected of containing one or more bacterial
cells, one or more microbeads conjugated with a capture antibody
capable of specifically binding a selected type of bacterial cell
at a first epitope, and a fluorescently labeled detection antibody
capable of specifically binding the selected type of bacterial cell
at a second epitope;
[0019] (c) directing the plurality of aqueous microdroplets into
the microdroplet array chamber;
[0020] (d) obtaining a fluorescence image of the microdroplet array
chamber using the fluorescence imaging microscope; and
[0021] (e) measuring fluorescence emission from the labeled
detection antibody in images of the microbeads, whereby the
presence of the selected type of bacterial cell in the sample is
detected when fluorescence emission from the labeled detection
antibody overlaps with an image of one or more of said microbeads.
[0022] 2. The method of embodiment 1, wherein in step (e) an
intensity of said fluorescence emission is proportional to the
number of bacteria bound to the microbead. [0023] 3. The method of
embodiment 1 or embodiment 2 which is carried out in multiplex
format using two or more types of microbeads, each type of
microbeads conjugated with a capture antibody that specifically
binds a different type of bacterial cell, and using two or more
types of distinctly fluorescent labeled detection antibodies, and
wherein two or more types of bacteria are detected simultaneously.
[0024] 4. The method of embodiment 3, wherein each type of
microbeads is labeled with a distinct fluorescent label, such as a
unique concentration of a Europium dye associated with each type of
microbeads. [0025] 5. The method of any of the previous
embodiments, wherein one or more reagents are added to the aqueous
microdroplets after their formation using a droplet merging
junction. [0026] 6. The method of any of the previous embodiments,
wherein aqueous microdroplets are sorted and routed to a selected
fluidic pathway or chamber according to fluorescence detected in
the aqueous microdroplets. [0027] 7. The method of any of the
previous embodiments, wherein one or more aqueous microdroplets are
routed outside the device for collection, further characterization,
and/or culturing of bacterial cells contained therein. [0028] 8.
The method of embodiment 7, wherein further characterization is
performed comprising analyzing one or more genes or the expression
thereof of a collected bacterial cell. [0029] 9. The method of any
of the previous embodiments, further comprising analyzing a
phenotype of one or more bacterial cells in an aqueous
microdroplet. [0030] 10. The method of embodiment 9, wherein the
phenotype is antibiotic sensitivity, and wherein the aqueous
microdroplets comprise an antibiotic suspected of killing or
hindering growth of the selected type of bacteria, and bacterial
growth and/or viability in the microdroplet is assessed. [0031] 11.
The method of any of the previous embodiments, wherein the sample
is a patient sample selected from the group consisting of urine,
blood, serum, plasma, sputum, or a lavage fluid. [0032] 12. The
method of embodiment 11, wherein the patient sample is urine, and a
urinary tract infection is diagnosed. [0033] 13. The method of
embodiment 11, wherein the patient sample is blood, serum, or
plasma, and sepsis is diagnosed. [0034] 14. The method of
embodiment 11, wherein the patient sample is sputum or a lavage
fluid, and a pulmonary or gastric infection is diagnosed. [0035]
15. The method of any of the previous embodiments, wherein the
aqueous microdroplets further comprise one or more additional types
of microbeads, each type conjugated with a capture antibody capable
of specifically binding an analyte present in or suspected of being
present in the sample, and one or more distinctly fluorescently
labeled detection antibodies capable of specifically binding the
analyte. [0036] 16. The method of embodiment 15, wherein the
analyte is IL-6 or IL-8. [0037] 17. The method of any of the
previous embodiments, wherein said microbeads are non-magnetic.
[0038] 18. A method of analyzing a cell phenotype, the method
comprising the steps of:
[0039] (a) providing a microfluidic device capable of forming
aqueous microdroplets in oil, the device comprising a translucent
microdroplet array chamber, and providing an imaging
microscope;
[0040] (b) preparing a plurality of aqueous microdroplets in oil
using the microfluidic device, each microdroplet comprising a
sample containing or suspected of containing one or more cells and
one or more reagents for analyzing a phenotype of said cells;
[0041] (c) directing the plurality of aqueous microdroplets into
the microdroplet array chamber;
[0042] (d) obtaining an image of the microdroplet array chamber
using the imaging microscope; and
[0043] (e) measuring an optical signal from said reagent, whereby
information regarding the phenotype of said cells is obtained.
[0044] 19. The method of embodiment 18, wherein the reagent is an
antibody or antibody-conjugated microbead, a fluorescent dye, cell,
nucleic acid, peptide, protein, vaccine, or pharmaceutical agent.
[0045] 20. The method of embodiment 18 or embodiment 19, wherein
the phenotype is cytokine secretion by the cells, and the reagents
comprise a microbead conjugated capture antibody and a fluorescent
labeled detection antibody, wherein both antibodies specifically
bind to said cytokine. [0046] 21. The method of embodiment 18 or
embodiment 19, wherein the phenotype is cell viability, and the
reagents comprise a fluorescent indicator of live vs. dead cells.
[0047] 22. The method of embodiment 18 or embodiment 19, wherein
the phenotype is susceptibility to an antitumor agent, the cells
comprise tumor cells, and the reagents comprise the antitumor
agent. [0048] 23. The method of embodiment 18 or embodiment 19,
wherein the phenotype is activation of an immune response, the
cells comprise T lymphocytes, and the reagents comprise antigen
presenting cells. [0049] 24. The method of embodiment 18 or
embodiment 19, wherein the phenotype is the presence of a
biomarker, and the reagents comprise a microbead conjugated capture
antibody and a fluorescent labeled detection antibody, wherein the
capture antibody specifically binds to an epitope on a selected
cell type and the detection antibody specifically binds to said
biomarker. [0050] 25. The method of embodiment 18 or embodiment 19,
wherein the phenotype is the action of a pharmaceutical agent on
the cells, and the reagents comprise an optical indicator of an
effect of the pharmaceutical agent on the cells. [0051] 26. The
method of any of embodiments 18-25 which is carried out in
multiplex format, and two or more phenotypes are analyzed
simultaneously. [0052] 27. The method of any of embodiments 18-26,
wherein one or more additional reagents are added to the aqueous
microdroplets after their formation using a droplet merging
junction. [0053] 28. The method of any of embodiments 18-27,
wherein aqueous microdroplets are sorted and routed to a selected
fluidic pathway or chamber according to an optical signal detected
in the aqueous microdroplets. [0054] 29. The method of any of
embodiments 18-28, wherein one or more aqueous microdroplets are
routed outside the device for collection, further characterization,
and/or culturing of cells contained therein. [0055] 30. The method
of any of embodiments 18-29, wherein phenotype analysis comprises
analyzing one or more genes or the expression thereof of one or
more of said cells.
BRIEF DESCRIPTION OF THE DRAWINGS
[0056] FIGS. 1A-1D show components of a microfluidic device for
detection and quantification of bacterial cells in a fluid sample.
FIG. 1A shows a microdroplet array (left side) and a droplet
distribution mechanism (right side). FIG. 1B show a droplet merging
junction. FIG. 1C shows a sample droplet containing fluorescent
microbeads detecting bound bacteria; FIG. 1D is a schematic
illustration of the components used in the microdroplet based
detection of bacteria.
[0057] FIG. 2 shows a schematic illustration for multiplex
detection of bacteria using bead-based immunoassay for capture of
E. coli, Klebsiella pneumoniae, Enterobacter species, Pseudomonas
aeruginosa, and Proteus as well as for cytokines.
[0058] FIG. 3A shows two fluorescently distinct beads encoded with
different concentration of Eu (0.1M for dimmer and 1M for the
brighter bead). FIG. 3B shows the detection of one of the analytes
with secondary antibodies conjugated to FITC captured only on the
1M Eu bead.
[0059] FIGS. 4A-4C show a polydimethylsiloxane (PDMS) microfluidic
chip generated using standard soft lithography methods, combining
functionalities of droplet generation and an incubation chamber
array of 1000 droplets. FIG. 4A presents a schematic illustration
of the design. FIG. 4B shows droplet generation and droplet array
of the device. FIG. 4C shows PDMS/glass chip optics for signal
detection, and PR-PR to facilitate microscopy control and data
acquisition.
[0060] FIG. 5 shows the fluorescence intensity of the microbead
after capturing the analyte. Each spike represents a bead, and its
fluorescence is proportional to the number of bacteria bound.
[0061] FIG. 6A shows a schematic illustration of the fluorescence
detection and white light alignment system. Laser-filter
combinations are chosen to allow multiplexed detection of up to 3
distinct fluorochromes. FIG. 6B shows how droplets can be sorted
using dielectrophoresis and based on the measured fluorescence
signal minimal cross-talk between channels. Beams can be expanded
with cylindrical lenses and then focused to a slit though a
60.times. microscope objective at different positions along the
channel.
[0062] FIGS. 7A and 7B show droplet merging technology
incorporation into the microfluidic platform device. FIG. 7C shows
a PDMS glass chip interface that allows creating fast and reliable
fluidic connections to PDMS-on-glass devices from glass based
devices.
[0063] FIG. 8A shows replication of bacteria in droplet over the
course of time. FIG. 8B shows capturing single bacteria on a bead
sensor. Note, in this panel, only one bead was present in the
droplet which allowed single bacteria capturing to a bead. FIG. 8C
shows bacterial intradroplet growth with and without levofloxacin
at 1 mg/L.
[0064] FIG. 9A is a schematic representation of a prior art device
for forming aqueous microdroplets in oil, the microdroplets
containing a mixture of a liquid sample and a suspension of
microbeads. The microdroplets are distributed into the droplet
array in the lower half of the figure. FIG. 9B shows a device
according to the present invention, in which a droplet merging
junction 20 for adding a reagent to preformed microdroplets prior
to incubation has been added between the upper half, after droplet
forming junction 10 and before microdroplet array 30.
[0065] FIGS. 10A-10G illustrate cell co-encapsulation in a droplet
microfluidic platform. FIG. 10A shows a schematic of an integrated
three-inlet droplet generation and microarray device. FIG. 10B
shows the generation of nanoliter droplets. FIG. 10C shows droplets
loaded in a microarray for stable docking. FIG. 10D shows
co-encapsulation of three types of cells into droplets. FIG. 10E
shows cellular exocytosis observed in a droplet. Inset shows a
magnified image of vesicles secreted by DCs at 4 hours. FIG. 10F
shows the morphology of single DC and T cells in a droplet. Inset
shows a magnified image of a dendrite extension by a DC. FIG. 10G
shows blebbing of cell membrane prior to cell death. Inset shows a
fluorescence image of a cell (labeled with calcein-AM) membrane
deformation. Scale bar: 20 .mu.m.
[0066] FIGS. 11A-11D show dynamic monitoring of interactions
between activated DCs and T cells in microfluidic droplets. FIG.
11A shows DCs that were pulsed with ovalbumin-FITC (100 .mu.g/mL,
16 hours) and CCL21 (25 ng/mL, 2 hours) and co-encapsulated with
untreated T cells in droplets. OVA-FITC expression on DC surface is
indicated by arrowheads. T cells are labeled with CMTPX tracker,
which is transferred to the DCs over time. Images were obtained
every 5 minutes. Scale bar: 20 .mu.m. FIG. 11B shows analysis of
the types of interaction between DC and T cells: no interaction
over a period of 5 hours, continuous interaction due to conjugate
formation, and discontinuous interaction defined by short periods
of attachment and detachment. DCs were either activated by
pre-treatment with OVA-FITC and CCL21 (Ag activated) or untreated
(Non activated). FIG. 11C shows cells undergoing discontinuous
interaction, further categorized into transient (<10 minutes of
contact) and stable (>10 minutes) interaction. FIG. 11D shows
the distribution of contact times between DC and T cells (outliers
are indicated).
[0067] FIGS. 12A-12C show co-encapsulation of tumor-lysate pulsed
DC, T cells, and tumor cells (RPMI-8226 multiple myeloma cell
line). FIG. 12A (top panel) illustrates the various stages of
interaction between the immune and tumor cells below in FIGS. 12B
(middle panel) and 12C (lower panel). Movement of DC and T cells
are indicated by the black arrow while movement of T cells and
tumor cells are indicated by the lighter arrow. Frames (a)-(e)
depict sequential events. (a) Freely motile DC and T cells move
towards each other within droplets. (b) DC-T cell conjugates are
formed. (c) DC-T cell conjugates dissociate and cells become motile
again. T cells and tumor cells move towards each other and
establish contact. (d) T cells dissociate from tumor cell. (e)
Tumor cells depict morphological changes, blebbing and membrane
rupture. (f) Tumor cell death indicated by uptake of ethidium
homodimer. FIG. 12B shows microscopic images of specific stages of
interaction described in (A) observed in droplets. FIG. 12C shows
magnified images of the corresponding panels shown in FIG. 12B.
Scale bar: 20 .mu.m.
[0068] FIGS. 13A-13D show DC-T cell interaction and dynamic calcium
signaling in droplets. FIG. 13A shows co-encapsulation of naive T
cell and DC stimulated with OVA-FITC (100 .mu.g/mL). DCs
demonstrate morphological change in droplets over time. FIG. 13B
shows the increase in calcium transient in T cell following contact
with DC. FIG. 13C show non-contact mediated increase in T cell
calcium level. Insets of FIGS. 13B and 13C show: fluorescence
images of the corresponding T cells. Scale bar: 50 .mu.m. FIG. 13D
shows representative traces of normalized fluorescent intensity
(N.F.I) of Fluo-4 in T cells under various states of conjugation
with DC:(a) DC-T cells in contact throughout experimental duration;
(b) Cell contact initiated at t=2 min, indicated by the square and
dissociated at t=12 min, indicated by the triangle; (c,d) No
contact observed between DC and T cells throughout experimental
duration.
[0069] FIG. 14 is a schematic illustration of IgE-dependent
cellular responses to allergy.
[0070] FIG. 15 is a schematic illustration of an allergen-driven,
dendritic cell mediated maturation process of a T cell to a Th2
cell. The figure shows several receptors and secretion monitoring
targets that can be used to follow the process.
[0071] FIG. 16A is a schematic illustration of IgE-dependent
basophil activation process carried out in a microdroplet. FIG. 16B
shows lipopolysaccharide induced IL-6 secretion from single
dendritic cells.
DETAILED DESCRIPTION OF THE INVENTION
[0072] The microfluidic device of the invention allows for
compartmentalizing a desired volume, up to and including the total
volume, of a biological sample, or a dilution or concentrate
thereof into micro-sized aqueous droplets, which serve as
individual nanoliter reactors. The microdroplets can be used
together with bead-based or other detection assay reagents to
generate an incubation array of nanoliter droplets for analysis
(FIG. 1A). The microfluidic device and its related methods of use
for cell detection and analysis in microfluidic droplets constitute
a platform or system for performing a wide variety of single
cell-based bioassays. Furthermore, the platform also includes
controlled delivery of reagents to cells for analysis; such
reagents can include antimicrobials as well as cell proliferation
and/or LIVE-DEAD assay reagents for susceptibility studies (FIG.
1B). The platform further allows simultaneous and automated
monitoring of several reactions in the same microfluidic chip or
reactor (i.e., multiplex diagnostic analysis), thus increasing
throughput and decreasing time for detection and reagent use. The
platform uses a two-phase system in which a sample containing live
cells and bead-based and/or other assay reagents is
compartmentalized into a series of individual aqueous microdroplets
(1 pL to 10 nL volume per microdroplet) surrounded by an oil which
is immiscible with water. (38-45) Advantages of this droplet-based
technique include the physical and chemical isolation of droplets,
eliminating the risk of cross-contamination; the fast and efficient
mixing of reagents and gases that occurs inside droplets; the
ability to digitally manipulate droplets at a very high throughput
rate (up to 1000 droplets/sec); the ability to incubate stable
droplets off-chip and reintroduce them into the microfluidic
environment for further processing and analysis; and the absence of
moving parts on the chip, such as integrated valves or pumps.
(38-45) Further, the nanoliter microenvironment allows efficient
gas exchange which is necessary to ensure viability of encapsulated
cells for use in susceptibility testing.
[0073] In certain embodiments, antibody-conjugated microbeads are
co-encapsulated with patient samples in microdroplets to provide an
ultrasensitive, specific, and fast immunoassay. (46) For example,
bacteria can be captured on a bead surface and then specifically
identified through binding of a fluorescently labeled detection
antibody. Thus, live bacterial cells present in a patient sample
are captured and then detected on a bead surface allowing the
detection resolution of one or more bacterial cells per bead in
from about 5 minutes to about 2 hours, such as in about 10, 20, 30,
40, 50, 60, 90, 100, or 120 minutes. The high throughput droplet
generation is typically at a rate of about 200 pL total droplet
volume per second, and analysis capability by fluorescent imaging
is about 500-1000 droplets per second, allowing screening the total
sample volume directly (e.g., 100 .mu.l sample of urine or BAL
fluid) in <1 hour and determining phenotypic susceptibility
results within 3 hours. The same microbead-based immunoassay
technology can be used simultaneously to quantify cytokines of
interest in the same microdroplets. (47) In addition, the system
can operate as a fluorescence-activated droplet sorting (FADS)
system, interrogating the entire reaction volume and sorting the
resulting droplets based on the results. However, unlike other
forms of droplet sorting, the bacterial cells remain encapsulated
in droplets and can be identified individually post-sorting. This
property allows efficient pathogen isolation after detection for
susceptibility studies.
[0074] Herein, disclosed is a robust, multiplex platform for rapid
microbial diagnostics, antimicrobial susceptibility testing, and
use of inflammatory makers for prognostic profiling. In particular,
an ultra-sensitive assay has been developed for detection of the
most common causes of multidrug-resistant UTI: Escherichia coli,
Klebsiella pneumoniae, Enterobacter, Pseudomonas aeruginosa, and
Proteus. The generated bead-based sensor can be used to
specifically and sensitively detect a bacterial level of 1000 to
>100000 CFU/ml of urine, consistent with clinically relevant
levels found in patients with UTI. Furthermore, the bead-based
assay can be adapted for multiplex analysis of several pathogens
simultaneously. The ability to perform such multiplex assay
experiments facilitates the completion of patient sample analysis
for possible causes of disease as well as reduce reagent cost and
turnaround time. In particular, different beads have been generated
that can be analyzed simultaneously by encoding each
probe-functionalized bead type via an avidin-biotin bridge with a
specific bacterial capturing antibody. Such beads previously have
been functionalized with different antibody probes for simultaneous
analyte detection. (47-51) In addition, the same bead-based
approach is used for analysis of the inflammatory cytokine
profile.
[0075] The devices and method of the present invention can be used
to detect, quantify, and/or characterize a phenotype of bacteria or
other cellular microbes present in a wide variety of infections or
other pathological conditions. For example, they can be used in
connection with microbes underlying urinary tract infections, such
as Escherichia coli, Enterococcus faecalis, Proteus mirabilis,
Stenotrophomonas maltophilia, Staphylococcus saprophyticus,
Pseudomonas aeruginosa, Enterobacteriaceae species, Klebsiella
species, and a fungus, Candida albicans. They can be used in
connection with microbes underlying sepsis, including Escherichia
coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Streptococcus
pneumoniae, Streptococcus pyogenes, Staphylococcus aureus,
Enterobacter species, Proteus species, and Candida albicans. They
can be used in connection with microbes underlying pulmonary
infections, such as Pseudomonas aeruginosa, Klebsiela pneumoniae,
Streptococcus pneumoniae, Haemophilus species, Staphylococcus
aureus and Mycobacterium tuberculosis. They can be used in
connection with microbes underlying gastrointestinal infections,
such as Helicobacter pylori, Escherichia coli, Salmonella,
Shigella, Campylobacter jejuni, Staphylococcus and Yersinia.
[0076] Also disclosed is integration of the bead assay into a
droplet-based microfluidics device that allows for co-encapsulation
of the biological sample and bead-based bioassay reagents for
bacterial and cytokine capture and later detection. Compared to
standard bulk immunosorbent assays, the microfluidic droplet
platform presented here reduces the reagent volume by four orders
of magnitude per reaction, while fast reagent mixing reduces the
detection time from hours to minutes. This platform is a
significant leap forward in diagnostic assay miniaturization. Also
contemplated is the use of droplet merging technology, which allows
delivery of the antibiotics or other reagents into each droplet
that contains previously-captured bacteria for susceptibility
testing. Antibiotic growth inhibition and bactericidal activity is
detected using optical and fluorescence based data integration.
[0077] Use of the system for detection and susceptibility testing
of pathogens in patient urine samples is disclosed. Assay readout
is optimized to yield qualitative (species) and quantitative (e.g.,
CFU/mL) readout, which is sufficient to establish UTI based on
clinical cutoffs used for diagnosis. Furthermore, the ability of
the system to determine susceptibility of isolates against select
antimicrobials has been performed. In addition, the use of
multiplex evaluation inclusive of cytokine measurements allows for
predicting those patients at greatest risk of pyelonephritis,
sepsis, and hospitalization. This patient group can then be
targeted for early aggressive treatment with directed antimicrobial
therapy to mitigate morbidity.
[0078] Characterization of the heterogeneity in immune reactions
requires assessing dynamic single cell responses as well as
interactions between the various subsets of immune cell subsets.
However, there are currently few methods available that allow
dynamic investigation of immune cell interactions, and other types
of interactions among freely dispersed cells, without physically
constraining the non-adherent cells. However, the microfluidic
droplet microarray platform of the present invention permits rapid
functional analysis of single cell responses and co-encapsulation
of heterotypic cell pairs, thereby making possible the evaluation
of the dynamic activation state of primary T cells, and other
cellular functions and phenotypes.
[0079] The microfluidic device and methods of the present
invention, through their ability to isolate and maintain single
cells, pairs of cells, or small groups of three or more cells, make
it possible to analyze various cell phenotypes and cell-cell
interactions. These include, but are not limited to, cell
viability, susceptibility of tumor cells to an antitumor agent,
activation of an immune response (such as activation of T
lymphocytes, B lymphocytes, dendritic cells, or other immune system
cells), the effectiveness of a cellular vaccine (such as a
dendritic cell vaccine), the presence or absence of a biomarker,
and the action of a pharmaceutical agent on a target cell or
non-target cell of interest (i.e., generation of dose-response
curves or the determination of inhibition constants or binding or
dissociation constants, or the observation of cellular level signal
transduction events related to the mechanism of action of a drug or
a side effect of a drug). Of particular importance is the ability
to study the responsiveness of a patient's own immune cells against
a tumor of the patient. This can be useful to evaluate the
effectiveness of a cellular vaccine. The cancer can be, for
example, a solid tumor, liquid tumor, hematologic tumor, renal cell
cancer, melanoma, breast cancer, prostate cancer, testicular
cancer, bladder cancer, ovarian cancer, cervical cancer, stomach
cancer, esophageal cancer, pancreatic cancer, lung cancer,
neuroblastoma, glioblastoma, retinoblastoma, leukemia, myeloma,
lymphoma, hepatoma, adenoma, sarcoma, carcinoma, blastoma, or
cancer of the colon, lung, kidney, liver, endometrium, cervix,
ovary, thyroid, skin, or central nervous system. Several specific
uses for cell phenotype assays are summarized in the examples
below.
EXAMPLES
Example 1
Microsphere-Based Assay for Simultaneous Analytical Detection of
Common Uropathogens
[0080] Common causative agents for UTI, including Escherichia coli,
Klebsiella pneumoniae, Enterobacter, Pseudomonas aeruginosa, and
Proteus, can be detected in a multiplex assay. Multiplex bead array
assays can be found as far back as 1977. (50-54) A wide assortment
of tests have been devised for bead-based assays using both
immunological and molecular ligands. However, a robust bead-based
assay to capture and analyze bacteria has not yet been developed.
Here, a bead-based protocol is disclosed with ultrahigh detection
sensitivity and specificity of antigen-antibody reactions to
identify bacterial presence in urine samples. The multiplex
capabilities of the assay were used to detect several bacterial
pathogens in urine samples simultaneously. The developed bead based
detection protocol was validated for specificity and sensitivity as
well as calibrated for determining the bacterial inoculum in the
sample.
Preparation of a Bead Sensor for Bacteria and Cytokine
Detection
[0081] So called "bar-coded" microbeads have been used in
bead-based arrays (i.e., in suspension or liquid arrays). These
techniques have several advantages over capturing bacteria on a
flat surface such as an ELISA plate: (1) Beads can have larger
surface areas than planar chips. This means that more captured
bacteria can be immobilized on the bead, and, thus, bead-based
arrays are more likely to detect a wide range of target pathogens.
(2) Detection is faster and sensitivity is equal to or higher than
that of ELISAs because the interaction between beads and target
molecules can be nearly comparable with solution-phase kinetics.
(3) Target molecules can be collected by using flow cytometry such
as fluorescence-activated cell sorting (FACS), such as an automated
plate-based BD FACSArray.TM. bioanalyzer, BD FACS.TM.. (4)
Large-scale fabrication and surface modification is possible, and
the prepared beads can be stored. Thus, customization is possible
by selective mixing of antibody-conjugated microbeads. (5) Beads
can be used with a combination of microfluidic devices to detect
trace amounts of bacteria in an automated manner.
[0082] In the present protocol, the identification of bacteria in a
urine sample includes two major steps: 1) the capture of target
bacteria from the sample, and 2) the identification of the captured
bacteria via association with a bar-coded microbead. In addition,
bead-based detection of inflammatory cytokines such as IL-6 and
IL-8 present in urine samples of infected patients is employed. An
example strategy is illustrated in FIG. 2. In this protocol, focus
is on development of bead-based detection for the following Gram
negative bacteria: E. coli, Klebsiella pneumoniae, Enterobacter
species, Pseudomonas aeruginosa, and Proteus, and for IL-6 and
IL-8. Capturing antibodies are biotinylated with EZ-Link
NHS-PEG4-Biotin (Thermo Scientific, USA) according to the
manufacturer's protocol and are diluted to a final concentration of
0.5 mg/ml in PBS with 0.005% (v/v) Tween-20 (Sigma, USA). The
purified antibody is applied to streptavidin conjugated polystyrene
microspheres (Spherotech) at a ratio of 20 .mu.g of IgG per mg
particles. The microcentrifuge tube containing the mixture is
shaken at RT for 90 min. Unbound active sites of the bead are
blocked with BlockAid (B-10710, Invitrogen, USA) for one hour.
Finally, the microspheres are washed in PBS (Sigma, USA) with 0.5%
(w/v) BSA (Sigma, USA), diluted to a final concentration of 0.5
mg/ml, and stored at 4.degree. C. Detection antibodies are labeled
with Alexa Fluor 488 (Invitrogen, USA) according to the
manufacturer's protocol.
[0083] Commercially available antibodies are available for each
species (and/or can be developed) and may be investigated as
described below for performance characteristics. For example, for
preparation of bead capture of Klebsiella pneumoniae, avidinylated
beads may be conjugated to biotinylated anti-K. pneumoniae
antibodies (ab20947 Abcam) and detected with FITC-conjugated rabbit
polyclonal antibody to Klebsiella (LS-C103383 LS Bio Inc); for
capture of Enterobacter cloacae, avidinylated beads are conjugated
to biotinylated anti-E. cloacae antibody (ab36931 Abcam) and
detected with FITC-conjugated mouse monoclonal antibody to
Enterobacter cloacae (GTX41313GeneTex); for Pseudomonas aeruginosa
capture, avidinylated beads are conjugated to biotinylated
anti-Pseudomonas aeruginosa antibodies (PA1-73116 Thermo Scientific
(Pierce Biotech antibody) and detected with FITC-conjugated rabbit
polyclonal antibody to P. aeruginosa (PA1-73117 Thermo Scientific
(Pierce Biotech antibody); etc. Beads for detection of specific
bacterial species are chemically bar-coded for individual
identification.
[0084] Previously developed bar-coded multiplex microsphere arrays
in which the microspheres are functionalized with different
antibody probes may be employed (FIGS. 3A-3B). Beads are
pre-labeled within different Europium concentrations, allowing them
be clearly differentiated via their fluorescent characteristics.
Specifically, in an embodiment, each bead may be created with a
distinct spectral characteristic for each target bacterial species
of interest. Distinct beads can be constructed that allow for
simultaneously distinguishing >10 analytes by this method.
Microspheres may be prepared from 50 .mu.L (5 mg) aliquots of a 5
.mu.m avidin-functionalized microsphere stock. The aliquots will be
washed in triplicate with 200 .mu.L of PBS and then be washed in
triplicate with 200 .mu.L of THF. A 200 pL solution of 0.1M
Europium (Eu) -dye (e.g., EuF.sub.2) in THF may then added, and the
microsphere suspension is then shaken in the dark for 2 h at room
temperature (RT). The reaction vessel may then be centrifuged, and
the microsphere pellet washed six times with 200 .mu.L of MeOH and
then washed six times with 300 .mu.L of PBS (0.154 M NaCl, 2.7 mM
KCl, 10 mM sodium phosphate, and 1.7 mM potassium phosphate, pH
7.4). The encoded microspheres may then be suspended in 500 .mu.L
of PBS with 0.01% Tween-20 and stored at 4.degree. C. in the dark.
An identical procedure may be followed for additional sets of
microspheres; however, the europium dye concentration in THF
solution may be incrementally increased up to 1 M. To illustrate,
FIG. 3A shows two fluorescently distinct beads encoded with
different concentrations of Eu (0.1M for dimer and 1M for the
brighter bead). In turn, each bead is conjugated to different
capturing antibodies, thus allowing different analytes to be
distinguished, despite using the same conjugated fluorophore (FITC)
on detection antibodies. FIG. 3B demonstrates the detection with
secondary antibodies conjugated to FITC of one analyte which was
captured only on the 1M Eu bead.
[0085] Though the success of bead based immunoassays depends on the
identification of high specificity antibodies to the multiple
pathogens, commercially available antibodies have demonstrated
adequate specificity. Use of distinct antibodies for capture and
detection allows additional tuning of specificity. Furthermore, if
necessary, embodiments may utilize custom recombinant antibody
services to generate specific panels of pathogen recognition
antibodies with AxioMx services. In addition, an embodiment may be
directed toboth rat and mouse hybridoma development options for
producing custom monoclonal antibodies to synthesize surface
exposed common genus or species antigen epitopes with Thermo
Scientific Pierce Custom Antibody Services (e.g., Enterobacterial
common antigen (55,56), Klebsiella genus core LPS epitope (57),
Pseudomonas Psl58, etc.
Integration of the Bead-Based Assay and Validation for Bacterial
Detection
[0086] To detect bacteria, microsphere-based assay components
developed above may be employed. Several lines of experiments may
be used during bead development. Specifically, the properties of
specific antibodies may be examined for both capture and specific
detection of bacteria. Initial experiments may be performed in
liquid solution and performance characteristics of reagents
determined by both fluorescent microscopy and automated plate-based
BD FACSArray.TM. bioanalyzer, BD FACS.TM. readout. Both methods
have been optimal for bead-based assay development in the past.
(50-54) For microscopy, a Zeiss 200 Axiovert microscope and AxioCAM
MRm digital camera setup already established in a laboratory may be
used. Image processing and analysis may be conducted using ImageJ
software or the like. Fluorescence emissions may be collected with
a set of filters (535-540 nm, 617-673 nm, 710-740 nm; Semrock) and
photomultiplier tubes (Hamamatsu). Fluorescence detection may be
driven at 100 kHz by a custom data-acquisition system (Labview;
National Instruments) that also allows signal processing and
statistical analysis.
[0087] Detection of bacteria of interest at various ratios to beads
may be examined in appropriate matrix (urine) admixed with diluents
that will be used during drop formation to replicate conditions in
the device described in Example 2. Embodiments are designed to
consistently and specifically detect one bacterium per bead, which
following the Poisson distribution, should mean achieving
consistent detection at bacteria to bead ratios of <1:10. The
quantitative aspects of signal (signal per bead x number of beads
positive) may be assessed through 10-fold dilution series to
establish a linear range of the assay.
[0088] In specificity studies, bead sensors may be tested to
determine whether they cross react with Gram-positive and
Gram-negative organisms that potentially can be found in urine. If
either reactivity or cross reactivity is found wanting, alternative
antibodies, combinations of antibodies, or different ratios of
antibodies may be examined either for capture or detection.
Furthermore, to improve analytical specificity, if necessary, a
strategy of using different antibodies for capture and detection
may be considered, thereby improving on the specificity of the two
antibodies individually. Specificity may be in line with other
detection methods such as MALDI-TOF and commercially available
biochemical panels where an identification at the species level is
generally acceptable if with >95% confidence, with no tolerance
for error out of the bacterial familial level. A test of a minimum
of 50 isolates for each species may be used to establish
sensitivity/detection and 100 isolates from other diverse species
to establish specificity of each iteration of bead format.
Inter-assay reproducibility goal is >95% at the LOD and
100.times. LOD in spiked matrix. The ability to find specific
antibodies that might potentially be problematic for a given
species and significant effort may need to be employed, mitigated
potentially by the fact that treatment and susceptibility cutoffs
for all Enterobacteriaceae is essentially the same. Lastly,
co-detection using different ratios of species of interest may be
used.
Example 2
Development of System for Differential Diagnosis and Antimicrobial
Susceptibility Testing
[0089] In this example, disclosed is a fully integrated droplet
based microfluidic device to detect and establish antimicrobial
susceptibility within intact droplets is disclosed. The technology
developed herein includes: 1) bead sensors and detection assay
reagents as well as urine sample co-encapsulation to generate
droplet based microreactors for detection, 2) droplet microarray
technology to analyze the captured bacteria and 3) droplet merging
technology for timely delivery of antimicrobials for susceptibility
testing.
Microbead-Based Assay Using IL-6 and IL-8 Cytokine
Interrogation
[0090] Two chips disclosed below are designed with variations on
geometry to meet the single bacteria interrogation and
co-encapsulation with assay reagents and antimicrobial agent
requirements. The first design presents a simpler approach, where
the polydimethylsiloxane (PDMS) chip is generated using standard
soft lithography methods, combining functionalities of droplet
generation and an incubation chamber array of 1000 droplets (FIGS.
4A-4C). The generation of monodisperse droplets is conducted in a
micro-channel through shearing flow at a flow-focusing zone that is
illustrated in FIGS. 4A-4C. Three perpendicular inlet channels form
a nozzle. The individual syringe pumps are used to control flow
rates of the central stream of the oil phase and the stream of sera
sample and the bioassay reagents (microsphere sensors and detection
antibodies) (FIG. 5). The channels are coated with Aquapel (PPG
Industries), and the flow rates are controlled by syringe pumps
(Harvard Apparatus). To form droplets, the flow rate ratio of water
to oil may be adjusted to the Qw/Qo=0.5 (Qw=1 .mu.L/min and Qo=2
.mu.L/min). The generated droplet volume is .about.1.8 nL
corresponding to a spherical droplet diameter of 150 .mu.m. This
chip is ideal for optimizing conditions for bacterial capture, flow
rates, etc. Once initial functional determinations are made with a
system that can be rapidly re-configured as necessary for
optimization and at relatively low cost, a mechanically more robust
PDMS/glass chip may be used that has the requisite characteristics
for inclusion in a diagnostic device. The chip also may be composed
of both robust glass for droplet generation and gas permeable PDMS
incubation for cell interrogation in droplets. This microdroplet
system enables rapid droplet generation to produce more than 10,000
monodispersed droplets per second ranging from 5 .mu.m to 250 .mu.m
in diameter. The flow rates in this device may be controlled by
Mitos pressure pumps that provide a pulseless liquid flow which is
ideal for applications where a highly stable flow is required, such
as droplet formation. In this device, bead based sensors and urine
sample are co-encapsulated in droplets that are formed at a
T-junction as described in FIG. 4A. These droplets then enter the
PDMS incubation part of the chip (FIG. 4D). To generate the PDMS
part of the device, the PDMS layer may be bonded to the glass chip
with serpentine geometry for cell incubation. This PDMS based
incubation part of the chip allows appropriate gas exchange to
maintain live co-encapsulated bacterial cells in microreactor
droplets during interrogation.
[0091] The limit of detection in spiked samples for the device
format may be determined. The device is validated for detection of
clinically-relevant (1000 to >100000 CFU/ml) levels of organisms
found in UTI patients. As it is possible that low levels of
bacteria (<1000 CFU/ml) may be present in patients without
symptomatic infection, or present as colonizing organisms in
patients with other pathogens, the fluorescence intensity may be
specifically calculated to identify clinically relevant quantities
of bacteria (i.e., 1000 CFU/ml). Determinations may be made whether
spiked pathogens of interest can be detected and to what degree
(10-fold serial dilutions) with a goal of detecting 1000 to 100000
CFU/ml within a 30 minute time frame.
[0092] In some embodiments, the analysis performed in Example 1 may
be repeated within the ScanDrop system to determine LOD,
quantitative linear detection range, and specificity for pathogens
of interest, realizing that the compartmentalization in nanodrop
format might change binding characteristics of antibody or FISH
probes and efficiency of microscopic readout. Therefore accuracy
and especially sensitivity may need to be re-established in this
alternative format. In some embodiments, quantitative performance
may be optimized via quantitative image analysis (See FIG. 5, bead
number positive.times.signal strength=quantity of bacteria per
volume analyzed), developing robust calibration curves for each
reagent bead assay through serial dilution studies. In some
embodiments, performance characteristics of bead capture-based
cytokine sandwich assays may be similarly incorporated and examined
confirming ability to specifically detect and quantitate
physiological cytokine concentrations.
Fluorescence Detection and Droplet Sorting Subsystem
[0093] To allow isolation and further manipulation of the detected
bacteria in the droplet for rapid susceptibility testing, a FADS
microfluidic device for droplet sorting can be used. The FADS may
be fabricated along the incubation channel of the device described
in FIGS. 4A-4D. An additional inlet channel may be designed to
introduce oil into the end of incubation channel to space the
droplets. Thus the incubation channel will be followed by a
sorting-shaped junction where droplets are actively sorted via
dielectrophoresis (FIG. 6). Droplets may be automatically sorted at
the outlet based on detection of up to 3 distinct fluorescent
markers. These may be exemplified by DAPI (blue), FITC (green) or
Cy5 (red), which are chemically stable, spectrally well-separated
dyes. The schematic of the reader-sorter subsystem is shown in FIG.
6. The channel may be illuminated simultaneously with up to 3 laser
slits. As droplets pass single-file through the field-of-view,
fluorescent signals may be detected with a bank of PMTs, and
droplets may be guided into 1 of 4 outlet channels using
dielectrophoresis (i.e. the three fluorophores plus an un-labeled
droplet channel). Major subsystem components are described as
follows:
[0094] Excitation Lasers: Up to 3 solid-state diode lasers
(Crystalaser Inc.) may be focused in slits across the microfluidic
channel corresponding to the excitation wavelengths of the three
fluorophores (405 nm, 488 nm and 633 nm). In combination with the
fluorescence detection filters, these are selected to be well
spectrally separated to allow multiplexed detection.
[0095] Photomultiplier Tubes (PMTs): A set of 3 PMTs may be used to
detect the fluorescent signal from labeled droplets. Fluorescent
light may be collected with a second 60.times. microscope
objective, split into 3 detection channels with 50-50
beam-splitters, and then filtered with appropriate band-pass
filters corresponding to each fluorophore (centered at: 450 nm, 550
nm, and 680 nm). The output of each PMT may be pre-amplified and
then acquired with a multi-function data acquisition board
(National Instruments) connected to a personal computer. Software
running on the PC allows real-time detection of fluorescent spikes
on each of the 3 detector channels. That the laser and filter
combinations can be adjusted to allow flexible operation with other
fluorophores as needed.
[0096] Sorting Junction: After passing through the laser slits,
droplets may be diverted into collection outlets using
dielectrophoresis. A micro-electrode may be deposited next to the
channel at the sorting junction during fabricated and connected to
a high voltage, programmable power supply (Stanford Research
Systems). Software written in Matlab may be used to control the
magnitude of and frequency the applied AC voltage applied across
the electrode on the basis of droplet fluorescent signature,
thereby controlling the magnitude of deflection and outlet channel.
The amplitude of the AC potential may be selected to be as small as
possible to minimize the possibility of shearing the droplets.
[0097] Alignment Optics: A white-light source and monochrome CCD
camera may be employed to allow alignment of the microfluidic chip
on the subsystem, and in particular to align orthogonal
illumination of the flow channel with the 3 laser slits and
detection optics.
Use of Droplet Merging Technology for Controlled Delivery of
Antimicrobials for Rapid Antimicrobial Susceptibility Testing
[0098] Herein, a glass microfluidic chip is disclosed that
facilitates fast and consistent merging of two individual droplet
streams (see FIGS. 7A and 7B), benefiting a wide range of
applications, including delivery of antimicrobials and bioassay
reagents to perform high throughput susceptibility testing. Unlike
other methods that incorporate expensive and bulky high voltage
electronics to merge droplets using electrostatic forces, this chip
feature works by simply "squeezing" droplets together in a
carefully designed merging chamber (FIG. 7B). The merger chip forms
droplets with cells at a T-junction. These droplets then enter the
droplet merging geometry, combining droplet containing cells with a
secondary reagent such as an antimicrobial agent. A "droplet merger
chip" or feature may be is designed for the merging of droplets in
the volume range 400 pL (90 .mu.m) to 900 pL (120 .mu.m). Since the
example embodiment device is made out of glass, it has an excellent
chemical compatibility and high visibility (excellent access for
optics). It is not toxic to cells (compared to chemical fusion),
does not required specialized equipment, and is inexpensive
(compared to electrofusion). Importantly, the fused droplets remain
confined within the array and can be monitored in fixed positions
during an extended incubation. In addition, the generated merged
droplets can be collected or introduced into previously described
PDMS based array device for interrogation.
[0099] The merger chip technology may be employed for incorporation
of antimicrobials for susceptibility testing in combination with
live/dead staining reagents. See FIG. 8. After capturing bacteria
on the bead surface, the merger chip may be used to test how
antimicrobials affect the growth and viability of captured
bacteria. For susceptibility testing, embodiments may include
merging antibiotics dissolved in Mueller-Hinton broth, and
pre-incubation for 2 hours to allow several doublings to occur, and
for antimicrobial static/cidal effects to manifest. Susceptibility
can therefore be simply measured by counting bacteria and observing
replication inhibition (FIG. 8). However, merging technology also
allows incorporation of non-toxic, dead-cell fluorescent staining
dyes (SYTOX Green, Orange, Blue etc. (63)), which may increase
specificity by providing a separate growth-independent measure of
cell viability. Specifically, live cells have intact membranes and
are impermeable to dyes such as SYTOX Green, which only leaks into
cells with compromised membranes. Therefore, inclusion of a dead
cell stain provides a rapid and reliable method for discriminating
live and dead bacteria. Importantly, as the system is dynamic,
permitting growth, bactericidal differences between susceptible and
resistant populations may be amplified during the incubation
period.
[0100] Antibiotics of interest may be trialed at multiple doubling
dilutions. Time-growth-kill kinetics may have to be determined
empirically and correlated with MIC data to determine optimal
predictive concentration for each antimicrobial of interest for
assignment of susceptible, intermediate, and resistant (CLSI)
categorization. Similar correlation analysis has been applied
previously in clinical systems such as the automated Vitek
(Biomerieux) and microscope-based Accelerate Diagnostics64
susceptibility testing systems to extrapolate MIC, and standardly
for determination of disc diffusion zone cutoffs. In some
embodiments, performance characteristics may be established for
several antibiotics of importance for treatment of GNB and last
lines of therapy for MDR GNB, specifically nitrofurantoin,
fosfomycin, trimethoprim-sulfamethoxazole (first-line agents); and
ciprofloxacin, ceftazadime, cefepime, meropenem,
piperacillin/tazobactam, and amikacin (MDR GNB agents).
[0101] Encapsulation and detection of clinically relevant
concentrations (1000 to >100000 CFU/ml) of green fluorescent
protein (GFP) E. coli K-12 directly from urine matrix have been
demonstrated without need for any prior concentration steps. As it
can be seen in FIG. 8A, replication of bacteria, several doublings
of numbers, within single droplets were demonstrated from t=0 to
t=1.5 hrs, enabling direct assessment of the susceptibility to
antibiotics such as levofloxacin (no replication) based on their
growth/replication inhibitor effects. Bacteria in FIGS. 8A-8C were
treated in urine. Next, in some embodiments, the capturing of a
single bacterium on a single bead previously functionalized with
capturing anti-bacterial antibodies was monitored. As can be seen
in FIG. 8B, the bacterium attachment was demonstrated only after 30
min of incubation. Bigger sized beads (18 .mu.m) may be
specifically functionalized with anti-bacterial antibodies to allow
more than one bacterium to attach to a single bead surface. The
droplet based culture approach allows physical and chemical
isolation of droplet cultures thus eliminating the risk of
cross-contamination. The fast and efficient mixing of reagents and
gases that occurs inside droplets allows capturing and detecting
the bacteria in a fast manner. In addition, demonstrated herein is
the ability to incubate stable droplets in the proposed droplet
array at 37.degree. C. for bacterial replication on a bead. Later,
the droplets which contain the detected bacteria at a very
high-throughput may be sorted and antimicrobials added for rapid
susceptibility testing utilizing droplet merging chip
technology.
Example 3
Diagnostic Validation
[0102] The use of a microfluidic system for bacterial detection and
quantification of select pathogens in patient clinical samples and
associated IL-6/IL-8 cytokine levels is exemplified.
[0103] Clinical urine culture samples are collected in urine
transport tubes that stabilize uropathogen numbers and viability,
and urine samples are stored at 4.degree. C. immediately after
specimens are cultured and are therefore available for later
analysis. Retrieved urine samples may be tested and correlated with
clinical reports and parallel determination of CFU/mL of specific
organisms. Clinically, urine cultures are plated using calibrated
loops and results reported out quantitatively in log10
concentration. More specifically, for clinical reporting, urine
culture results are divided into four quantitative categories: no
growth, <10,000, 10-100,000,and >100,000 CFU/ml. Isolates are
also speciated by the Vitek 2 (Biomerieux) automated identification
system. Biotype numbers (a numerical summary of biochemical
reactions) are determined for each isolate and identify potentially
unique strain subtypes.
Example 4
Killing of Tumor Cells by Dendritic Cell-Activated T Cells
[0104] The functional responses of activated effector immune cells
were investigated by utilizing the microfluidic droplet generation
and docking array platform of the present invention. Anti-tumor
immune responses of NK cells and T lymphocytes stimulated by
interaction with mature dendritic cells (DCs) were investigated.
While NK cells are known to target cancer cells non-specifically
(i.e., without previous antigenic exposure), T cells require
maturation signals from cognate DCs prior to target cell killing.
By co-encapsulating individual mature DCs, naive T cells and cancer
cells within a droplet, efficiency of DC-based vaccines against
cancer cells can be tested.
[0105] Immunological synapse formation was investigated between T
cells and DCs pre-exposed to cancer cell lysate. The activated T
cells then mediated the death of co-encapsulated cancer cells. The
rapid reaction kinetics in droplet microfluidics facilitated
cell-cell interaction and delivery of cytotoxic hits to cancer
cells within two hours in this integrated platform. The
microfluidic droplets also allowed determination of strong
heterogeneity during immune synapse formation with respect to
transient vs. stable interactions and the duration of T-DC
conjugate formation. Serial brief encounters were observed between
the same DC-T cell pair, which would not be possible with
microwells or hydrodynamic cell traps. Further detected were
contact dependent cancer cell lysis by NK cells, and quantified
heterogeneous profiles of cell conjugation, delivery of lytic hits
and target death. It was observed showed that a single NK cell
resulted in multiple cell deaths, sometimes interacting with up to
four target cells simultaneously. NK-mediated target cell lysis in
the presence of anti-PD-L1 blocking antibody was also
characterized, as the PD-1/PD-L1 axis is involved in promoting
immune escape in a number of solid and liquid tumors. Humanized
antibodies against PD-1 and PD-L1 are presently utilized in
clinical trials and have shown great promise in antitumor
immunotherapeutic treatments. In droplets, 50% single target cell
lysis was observed in significantly shorter duration compared to
control. Taken together, the data suggest that this integrated
droplet-based microfluidic platform provides an important tool for
dynamic real time analysis of synaptic communications and
downstream effector functions of immune cells.
[0106] The microfluidic device was similar to that described above.
The droplet generation junction was followed by a large docking
array consisting of 1000 trapping sites where the droplets were
stably arrested. Consistent droplet sizes of .about.100 .mu.m
diameter (i.e., 520 pL volume) were obtained by optimization of the
flow rates of the two phases (FIG. 10C). The cell encapsulated
droplets were maintained for up to 48 hours in a CO.sub.2-rich and
humidified atmosphere, and minimal droplet shrinkage was observed.
By coordinating individual inlet flow rates and optimizing initial
cell density, large numbers of droplets were routinely obtained
with co-encapsulation of all three types of individual cells (FIG.
10D).
[0107] Several types of cell co-encapsulation were performed using
this approach: T-DC interaction, TDC-cancer cell interaction and
NK-cancer cell interaction. unstimulated T cells derived from the
non-adherent fraction of peripheral blood mononuclear cells, and
mature DCs generated from adherent mononuclear cells cultured with
cytokines were added through separate inlets to ensure that cell
pairing and subsequent activation occurred only in the droplets.
Likewise, NK cells and cancer cells (RPMI-8226 cells, a multiple
myeloma line) were co-encapsulated in droplets by flowing through
separate fluid inlets, thus allowing the investigators to monitor
the early signaling events and synapse formation in this platform.
For these studies with two cell types, the third inlet was used to
perfuse media only. Since droplets provide a culture platform
highly compatible with non-adherent cells, it was possible to
observe a number of morphological features of the encapsulated
cells, including secretory vesicle formation (FIG. 10E), dendrite
extension by DCs (FIG. 10F), and membrane blebbing prior to cell
death (FIG. 10G). The results showed both continuous and
intermittent interactions between cell pairs, leading to
quantitative analysis of dynamic parameters corresponding to these
interactions (FIG. 11). In addition, all cellular secretions
remained undiluted within the droplets, leading to
noncontact-mediated activation of co-encapsulated cells while
minimizing stimulation of neighboring cells.
[0108] Mature DCs that had not specifically been loaded with Ag
demonstrated relatively low interaction with non-stimulated T
cells. Among the DC-T cell pairs co-encapsulated, 11% cells showed
short periods of interaction while most did not interact at all
(FIG. 11B). The duration of these interactions were either less
than 10 minutes (50%), or 10-20 minutes (33%) (FIG. 11D). No
interaction lasted longer than 35 minutes.
[0109] Next the dynamic interactions of chemokine-treated (CCL21),
Ag-loaded DCs and naive T cells was investigated at single cell
resolution. DCs were exposed to FITC-conjugated OVA (323-329)
peptides overnight, followed by treatment with CCL21 before
co-encapsulation in droplets with naive T cells (FIG. 11A). The
presence of lymphoid chemokines such as CCR7 ligands CCL19 and
CCL21 in the lymph node is known to regulate immune cell migration,
maturation and effector functions. A marked increase in the extent
of DC-T cell interaction was observed upon activation compared to
control conditions (FIG. 11B). The dynamic single cell analysis
also revealed strong heterogeneity in cellular interactions with
respect to DC-T cell conjugate formation. While 34% of the T cells
monitored showed no interaction with DCs, 16% remained conjugated
throughout the duration of the experiment (5 hours). The conjugated
cells showed lateral movement, in that the respective positions of
the T cells on the surface of the DCs changed with time (FIG. 11A,
right panel). The OVA-FITC peptide was observed expressed on the DC
surface. Initially the T cell and the DC formed a synapse away from
the site bearing the OVA-FITC peptide, but the contact site altered
over time and eventually settled at the site of the Ag at 50
minutes. This motility of T cells was observed in almost all T-DC
conjugates; however, the time required to reach the Ag-bearing site
varied widely between cells.
[0110] A large proportion of the T cells observed (50%) interacted
discontinuously and asynchronously with the co-encapsulated DCs,
forming short term contacts and disassociating repeatedly (FIG.
11B). Here, transient interaction was defined by <10 minutes of
cell complex retention. Longer interactions were considered stable.
As indicated in FIG. 11C, 58% of the T cells undergoing
discontinuous interaction depicted periods of stable contacts.
While the duration of the contacts varied from cell to cell, the
majority of the contacts lasted .ltoreq.40 minutes (FIG. 11D).
[0111] In addition to DCs activated with non-clinical triggering
signals, the efficacy of DCs expressing tumor antigen in priming of
T cell effector responses against a MM cell line was investigated
in microdroplets. Dendritic cell (DC)-based vaccines are being
pursued as therapeutic agents in an effort to induce clinically
meaningful anti-tumor immunity. Hybridomas generated by fusion of
patient-derived myeloma cells and autologous DCs present a broad
array of tumor associated antigens in the context of DC mediated
co-stimulation. In a clinical trial of patients undergoing
autologous transplantation, vaccination with DC/MM fusions
post-transplant resulted in the dramatic expansion of myeloma
specific T cells and the conversion of partial to complete response
in a subset of patients. In this study, DC vaccine cells activated
with tumor lysate were utilized, together with DC/MM fusion cells.
DCs matured by exposure to RPMI-8226 cell lysates were
co-encapsulated with unprimed T cells and RPMI-8226 cells in
droplets (FIG. 12A-12C). All three cells were initially separated
and freely motile, as illustrated schematically in FIG. 12A and
demonstrated in droplets in FIGS. 12B and 12C. Sequential
interaction of the cell types occurred in the droplets, with DCs
interacting with T cells first (FIGS. 12A-C(b)), followed by
T-cancer cell interaction (FIGS. 12A-C(c)), thereby recapitulating
the succession of events observed physiologically. Three distinct
time phases were observed in the droplets. Firstly, the DCs loaded
with tumor antigens demonstrated transient physical contact with T
cells in the order of .ltoreq.10-20 minutes. Then the DC and T cell
separated and a variable period of segregation was observed where
all three cell types remained unattached. In the third phase, T
cells formed conjugates with the RPMI-8226 cell for a period of
.about.20-30 minutes, which ended with cancer cell death (FIGS.
12A-C(e), (f)). These interactions took place over a total time
period of 2 hours, although the duration of DC-T interaction and
T-cancer interaction was heterogeneous between droplets.
Furthermore, cancer cell death occurred in two ways, either in
conjugation with the T cell or following separation of the cancer-T
cell complex. Cancer cell death was most commonly observed by cell
blebbing and membrane rupture, as well as uptake of ethidium
homodimer (FIGS. 12A-C(f)). These results demonstrate that
presentation of whole tumor derived antigen as lysate or DC/tumor
hybridoma results in the productive interaction between DC and T
cells resulting in T cell activation. While T cell activation
appeared to be dependent on the presence of antigen, killing in
this model was directed against allogeneic myeloma cell lines.
Example 5
Measurement of T Cell Activation by Dendritic Cells
[0112] The inventors tested whether the microfluidic droplet
platform was suitable for monitoring calcium signaling in T cells
following interaction with DCs. DCs were stimulated with 100
.mu.g/mL ovalbumin (OVA (323-329)) peptide conjugated with FITC
(Anaspec, Fremont, Calif.). The overall peptide sequence was
FITC-LC-IS QAV HAA HAE INE AGR-OH. The DCs were treated overnight
so as to promote antigen presentation on Major Histocompatibility
Complex II (MHC-II). The DCs were washed twice to remove the
suspended OVA-FITC in solution prior to encapsulation within
droplets. The stimulated dendritic cells and T cells pre-loaded
with the calcium indicator Fluo-4 were introduced from different
inlets. Monitoring of cell-cell contact and intracellular calcium
signaling began immediately after droplet generation and stable
docking in the trapping array.
[0113] In the lymph node, DCs are known to scan T cell populations
in an attempt to locate T cells of appropriate antigenic
specificity. DCs form both transient and stable contact with T
cells during antigen presentation, promoting T cell maturation,
signaling and proliferation. Immune synapse formation between DCs
and antigen presenting cells (APC) has been replicated in vitro;
however, given that T cells are non-adherent, it is difficult to
follow dynamic cell interaction of the same cell pair over
prolonged periods without constraining cell motility through
adhesion proteins or antibodies. Microfluidic droplets can
circumvent this problem by co-encapsulating DCs and T cells within
nanoliter volumes, thereby reducing cellular diffusion times while
permitting directed and random motility, cell conjugation and
dissociation as well as the possibility of repeated interaction
between each cell pair.
[0114] DCs were stimulated with FITC-conjugated ovalbumin (referred
to as OVA-DC) peptide, a commonly used antigen that is ingested by
DCs and presented to naive T cells in a major histocompatibility
complex II-bound manner. Co-encapsulation of DCs with T cells in
the microfluidic droplet array resulted in long-lasting (.gtoreq.90
minutes) as well as transient interaction of the two cell types
(FIG. 13A). Within droplets, DCs depicted remarkable morphological
changes and frequently extended dendrites, implying that DCs were
able to function adequately in this microenvironment. An increase
in cytosolic calcium transients was observed in the T cell
following interaction of the two types of cell (FIG. 13B). This
increase was extremely rapid and diminished over time even when the
DC-T conjugate persisted, suggesting the end of early activation
phase following initial contact (FIG. 13D(a)). Of note, the trends
of the transient calcium increase in the T cells stimulated by
OVA-DC were remarkably different compared to that observed in
ionomycin-stimulated T cells. Here fluorescence intensity was
observed to increase in narrow peaks, suggesting calcium spikes
rather than broad fluctuations or consistent increase/decrease.
[0115] Interestingly, T cells showed a non-contact mediated
increase in calcium signaling (FIG. 13D(cd)). This was observed at
later time points compared to the OVA-DC-contact mediated increase
in calcium levels, starting after approximately 30 minutes
post-encapsulation. The duration and peak of the increased calcium
levels differed from cell to cell. The mature DCs and T cells were
sequestered in minute volumes in the droplets, which serve as
nanoliter bioreactors and prevents dilution of cell-secreted
products. It is feasible that the DCs activated T cells despite the
lack of the contact via paracrine signaling.
Example 6
IgE-Dependent Manifestations of Allergy in Immune Cells.
[0116] Immediate hypersensitivity (allergy) to foods is dependent
upon allergen-specific IgE with exceptions for less common forms of
food allergy such as eosinophilic esophagitis and other
gastrointestinal conditions. Immune responses that regulate the
allergen-specific IgE, IgG, and IgA repertoire--all of which likely
contribute to clinical heterogeneity--depend upon cell-cell
interactions such as those between dendritic cells and CD4 T cell
subsets (see FIG. 14). In addition, IL-4, IL-5, and IL-13, produced
by allergen-specific CD4 Th2 cells, play a major role in driving
Th2 differentiation and induces IgE production by allergen-specific
B cells (FIG. 14). Therefore, characterization of differences in DC
responses and DC-T cell interactions between human food-allergic
and non-allergic subjects is necessary to gain a better insight
into the role of DCs in sensitization and tolerance to food
allergens.
[0117] Basophils express the high affinity receptor for IgE (FceRI)
and represent a significant population of antigen-specific cells in
IgE-sensitized individuals that are capable of releasing histamine,
leukotrienes, cytokines and other mediators. As such, basophils are
both relevant tiomarkers' of IgE-mediated hypersensitivity and
potential targets of immunomodulatory interventions. In fact,
assays of IgE-dependent cellular responses, such as the basophil
activation test (BAT), have already been shown to be more
informative than assays simply detecting the presence of IgE but
because they are less feasible, they have been less studied and not
broadly pursued for clinical application. Furthermore distinct
phenotypes of basophils with potential relation to clinical allergy
and therapeutic potential of targeting basophils in preventing or
alleviating the development and progression of allergic
inflammation have been proposed. Thus it is important to study the
effects of immunotherapy on basophil to better understand
mechanisms of immunotherapy and evaluate basophil suppression as a
biomarker for immunotherapy.
[0118] The use of the microfluidic devices and microdroplet-based
encapsulation of the present invention is used to encapsulate and
analyze individually specific functional phenotypes of cells
relevant to allergy, such as food allergy. In addition, to cell
surface studies, this approach is used to collect data on secreted
molecules of single live cells or during DC-T synapse formation
utilizing microsphere based fluorescence assays which are
co-encapsulated in the microfluidic reaction droplets along with
interrogated cells. Secreted molecules from single cells
compartmentalized in the nanoliter droplet bioreactors quickly
reach detectable concentrations because of the small droplet volume
which allows rapid detection of live cellular secretion. Thus live
cell secretion and surface monitoring are obtained simultaneously
in a distinct microenvironment between two interacting cells, which
previously was possible using complicated and multi-step in vitro
and in vivo live-cell microscopy, together with immunological
studies of the outcome secretion of cellular interactions. In
addition, a fluorescence activated droplet sorting (FADS) system is
used to collect subpopulations of immune cells having selected
phenotypes.
[0119] The expression of CD86 can be followed in co-encapsulated T
cells and DC, as a reflection of the co-stimulatory signals
necessary for T cell activation (see FIG. 15). The interaction
between CD40 on DC and its T cell ligand (CD40L) also can be
followed to establish efficient activation of Th2 cell phenotype in
droplets during immunological synapse formation. The
co-encapsulation of T cell and DC in micro-reaction droplets is
accompanied by bioassay reagents including fluorescently labeled
anti-CD86 antibodies Cyanine 5(Cy5 red) and anti-CD40L antibodies
Fluorescein isothiocyanate (FITC green). The maturation phenotype
of the DC also can be followed by measuring IL-6, a cytokine that
plays an important role in lymphocyte activation, as well as IL-4,
IL-13, and IL-5 cytokines, secreted by Th2 cells (FIG. 15). For
these cytokine secretion measurements during DC-T cell
interactions, the cells are co-encapsulated along with
fluorescently labeled detection antibodies (anti-IL-6 FITC,
anti-IL-4 Cy3, anti-IL-5 CyS, anti-IL-15 APC antibodies) and four
microsphere sensors--SPHERO.TM. Avidin Coated Particles (0.9 .mu.m)
conjugated with 40 .mu.g biotinylated IL-6, IL-4, IL-13, and IL-5
antibodies (FIG. 15).
[0120] Three assays that have been applied recently to food
allergens are based on IgE-dependent basophil activation: the
histamine release test, the CD63-based basophil-test, and the
CD203c-activation assay. The co-encapsulation chip technology can
be used for co-encapsulation of previously IgE sensitized basophils
with crude peanut extract, in micro-reaction droplets along with
bioassay reagents which are fluorescently labeled detection
anti-CD63 antibodies (Cy5), anti-CD203c antibodies (FITC), as well
as anti-histamine antibodies Cy3 (see FIG. 16A). The increase in
CD63 and CD203c markers in response to an allergen as an increase
in fluorescence over time also can be studied. In addition,
allergen-induced (IgE-mediated) histamine release can be measured
in a dose-dependent microdroplet reaction. Specific phenotypes of
basophils could be obtained off chip using FADS technology.
[0121] The activation and monitoring of live single cells for
secretion and cell surface markers have been measured
simultaneously. In particular, droplet based technology can be
applied to simultaneously stimulate mouse DC maturation with an
immunological adjuvant, lipopolysaccharide (LPS), and to monitor
two phenotypic markers of DCs. The maturation phenotype of the live
DC was followed by measuring CD86 expression and IL-6 secretion. DC
were co-encapsulated with LPS and bioassay reagents (microsphere
sensors and antibodies). This method made it possible to
distinguish the responses of individual cells to LPS stimulation in
the confined volume of droplets. In addition to CD86, LPS induced
IL-6 secretion could be monitored from the same encapsulated single
DCs (FIG. 16B). The signal was detected in droplets after 10 min in
the array. Droplets with LPS stimulation contained IL-6 levels that
were significantly higher than droplets with no LPS, which showed
negligible IL-6 levels.
REFERENCES
[0122] 1. Hooton T M: Fluoroquinolones and resistance in the
treatment of uncomplicated urinary tract infection. International
journal of antimicrobial agents 2003, 22 Suppl 2:65-72. [0123] 2.
Gupta K, Hooton T M, Naber K G, Wullt B, Colgan R, Miller L G,
Moran G J, Nicolle L E, Raz R, Schaeffer A J, Soper D E:
International clinical practice guidelines for the treatment of
acute uncomplicated cystitis and pyelonephritis in women: A 2010
update by the Infectious Diseases Society of America and the
European Society for Microbiology and Infectious Diseases. Clin
Infect Dis 2011, 52(5):e103-120. [0124] 3. Barber A E, Norton J P,
Spivak A M, Mulvey M A: Urinary tract infections: current and
emerging management strategies. Clinical infectious diseases : an
official publication of the Infectious Diseases Society of America
2013, 57(5)719-724. PMCID: 3739462 [0125] 4. Nordmann P, Cuzon G,
Naas T: The real threat of Klebsiella pneumoniae
carbapenemase-producing bacteria. Lancet Infect Dis 2009,
9(4):228-236. [0126] 5. Kumarasamy K K, Toleman M A, Walsh T R,
Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske C
G, Irfan S, Krishnan P, Kumar A V, Maharjan S, Mushtaq S, Noorie T,
Paterson D L, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma J B,
Sharma M, Sheridan E, Thirunarayan M A, Turton J, Upadhyay S,
Warner M, Welfare W, Livermore D M, Woodford N: Emergence of a new
antibiotic resistance mechanism in India, Pakistan, and the UK: a
molecular, biological, and epidemiological study. Lancet Infect Dis
2010, 10(9):597-602. PMCID: 2933358 [0127] 6. Detection of
Enterobacteriaceae isolates carrying metallo-beta-lactamase--United
States, 2010. MMWR Morb Mortal Wkly Rep 2010, 59(24):750. [0128] 7.
Dortet L, Poirel L, Nordmann P: Worldwide Dissemination of the
NDM-Type Carbapenemases in Gram-Negative Bacteria. Biomed Res Int
2014, 2014:249856. PMCID: 3984790 [0129] 8. Spellberg B, Guidos R,
Gilbert D, Bradley J, Boucher H W, Scheld W M, Bartlett J G,
Edwards J, Jr.: The epidemic of antibiotic-resistant infections: a
call to action for the medical community from the Infectious
Diseases Society of America. Clinical infectious diseases : an
official publication of the Infectious Diseases Society of America
2008, 46(2):155-164. [0130] 9. Won S Y, Munoz-Price L S, Lolans K,
Hota B, Weinstein R A, Hayden M K: Emergence and rapid regional
spread of Klebsiella pneumoniae carbapenemase-producing
Enterobacteriaceae. Clinical infectious diseases: an official
publication of the Infectious Diseases Society of America 2011,
53(6):532-540. [0131] 10. van Duin D, Perez F, Rudin S D, Cober E,
Hanrahan J, Ziegler J, Webber R, Fox J, Mason P, Richter S S, Cline
M, Hall G S, Kaye K S, Jacobs M R, Kalayjian R C, Salata R A, Segre
J A, Conlan S, Evans S, Fowler V G, Jr., Bonomo R A: Surveillance
of Carbapenem-Resistant Klebsiella pneumoniae: Tracking Molecular
Epidemiology and Outcomes through a Regional Network. Antimicrobial
agents and chemotherapy 2014. [0132] 11. Hirsch E B, Tam V H:
Detection and treatment options for Klebsiella pneumoniae
carbapenemases (KPCs): an emerging cause of multidrug-resistant
infection. J Antimicrob Chemother 2010, 65(6):1119-1125. [0133] 12.
Munson E L, Diekema D J, Beekmann S E, Chapin K C, Doern G V:
Detection and treatment of bloodstream infection: laboratory
reporting and antimicrobial management. Journal of clinical
microbiology 2003, 41(1):495-497. PMCID: 149611 [0134] 13. Clark A
E, Kaleta E J, Arora A, Wolk D M: Matrix-assisted laser desorption
ionization-time of flight mass spectrometry: a fundamental shift in
the routine practice of clinical microbiology. Clin Microbiol Rev
2013, 26(3):547-603. PMCID: 3719498 [0135] 14. Tam V H, Hirsch E B,
Lasco T M, Gentry L O, Palmer H R: Correlation of hospital
carbapenem consumption and resistance trends in selected
gram-negative bacteria. Ann Pharmacother 2012, 46(7-8):1120-1122.
[0136] 15. Aitken S L, Beyda N D, Shah D N, Palmer H R, Lasco T M,
Koo H, Garey K W: Clinical practice patterns in hospitalized
patients at risk for invasive candidiasis: role of antifungal
stewardship programs in an era of rapid diagnostics. The Annals of
pharmacotherapy 2014, 48(6):683-690. [0137] 16. van Belkum A,
Durand G, Peyret M, Chatellier S, Zambardi G, Schrenzel J,
Shortridge D, Engelhardt A, Dunne W M, Jr.: Rapid clinical
bacteriology and its future impact. Ann Lab Med 2013, 33(1):14-27.
PMCID: 3535192 [0138] 17. Tan K E, Ellis B C, Lee R, Stamper P D,
Zhang S X, Carroll K C: Prospective evaluation of a matrix-assisted
laser desorption ionization-time of flight mass spectrometry system
in a hospital clinical microbiology laboratory for identification
of bacteria and yeasts: a bench-by-bench study for assessing the
impact on time to identification and cost-effectiveness. Journal of
clinical microbiology 2012, 50(10):3301-3308. PMCID: 3457442 [0139]
18. Coombs G W, Morgan J P, Tan H L, Pearson J C, Robinson J O:
Evaluation of the BD GeneOhm MRSA ACP Assay and the Cepheid
GeneXpert MRSA Assay to detect genetically diverse CA-MRSA.
Pathology 2013, 45(7):713-715. [0140] 19. Tenover F C, Canton R,
Kop J, Chan R, Ryan J, Weir F, Ruiz-Garbajosa P, LaBombardi V,
Persing D H: Detection of colonization by carbapenemase-producing
Gram-negative Bacilli in patients by use of the Xpert MDRO assay.
Journal of clinical microbiology 2013, 51(11):3780-3787. PMCID:
3889767 [0141] 20. Park K S, Kim J Y, Lee J W, Hwang Y Y, Jeon K,
Koh W J, Ki C S, Lee N Y: Comparison of the Xpert MTB/RIF and Cobas
TaqMan MTB assays for detection of Mycobacterium tuberculosis in
respiratory specimens. Journal of clinical microbiology 2013,
51(10):3225-3227. PMCID: 3811628 [0142] 21. Baron E J, Tenover F C:
Methicillin-resistant Staphylococcus aureus diagnostics: state of
the art. Expert Opin Med Diagn 2012, 6(6):585-592. [0143] 22. Baker
I, Leeming J P, Reynolds R, Ibrahim I, Darley E: Clinical relevance
of a positive molecular test in the diagnosis of Clostridium
difficile infection. The Journal of hospital infection 2013,
84(4):311-315. [0144] 23. D'Andrea M M, Venturelli C, Giani T,
Arena F, Conte V, Bresciani P, Rumpianesi F, Pantosti A, Narni F,
Rossolini G M: Persistent carriage and infection by
multidrug-resistant Escherichia coli ST405 producing NDM-1
carbapenemase: report on the first Italian cases. Journal of
clinical microbiology 2011, 49(7):2755-2758. PMCID: 3147842 [0145]
24. Hannan T J, Totsika M, Mansfield K J, Moore K H, Schembri M A,
Hultgren S J: Host-pathogen checkpoints and population bottlenecks
in persistent and intracellular uropathogenic Escherichia coli
bladder infection. FEMS Microbiol Rev 2012, 36(3):616-648. PMCID:
3675774 [0146] 25. Otto G, Braconier J, Andreasson A, Svanborg C:
Interleukin-6 and disease severity in patients with bacteremic and
nonbacteremic febrile urinary tract infection. The Journal of
infectious diseases 1999, 179(1):172-179. [0147] 26. Olszyna D P,
Prins J M, Dekkers P E, De Jonge E, Speelman P, Van Deventer S J,
Van Der Poll T: Sequential measurements of chemokines in urosepsis
and experimental endotoxemia. J Clin Immunol 1999, 19(6):399-405.
[0148] 27. Hedges S, Stenqvist K, Lidin-Janson G, Martinell J,
Sandberg T, Svanborg C: Comparison of urine and serum
concentrations of interleukin-6 in women with acute pyelonephritis
or asymptomatic bacteriuria. The Journal of infectious diseases
1992, 166(3):653-656. [0149] 28. Ciszek M, Paczek L, Bartlomiejczyk
I, Mucha K: Urine cytokines profile in renal transplant patients
with asymptomatic bacteriuria. Transplantation 2006,
81(12):1653-1657. [0150] 29. Fischer K, Hamza A, Eismann R, Amoury
M, Heynemann H, Fornara P: Differential diagnostic use of
interleukin patterns in patients being monitored after
transplantation. Clin Chim Acta 2001, 310(1):71-80. [0151] 30.
Hedges S, Svanborg C: The mucosal cytokine response to urinary
tract infections. International journal of antimicrobial agents
1994, 4(2):89-93. [0152] 31. Samuelsson P, Hang L, Wullt B, Irjala
H, Svanborg C: Toll-like receptor 4 expression and cytokine
responses in the human urinary tract mucosa. Infect Immun 2004,
72(6):3179-3186. PMCID: 415697 [0153] 32. Godaly G, Ambite I,
Svanborg C: Innate immunity and genetic determinants of urinary
tract infection susceptibility. Current opinion in infectious
diseases 2015, 28(1):88-96. PMCID: 4286230 [0154] 33. Rodriguez L
M, Robles B, Marugan J M, Suarez A, Garcia Ruiz de Morales J M: Do
serum C-reactive protein and interleukin-6 predict kidney scarring
after urinary tract infection? Indian J Pediatr 2013,
80(12):1002-1006. [0155] 34. Renata Y, Jassar H, Katz R, Hochberg
A, Nir R R, Klein-Kremer A: Urinary concentration of cytokines in
children with acute pyelonephritis. Eur J Pediatr 2013, 172(6):769-
774. [0156] 35. Jantausch B A, O'Donnell R, Wiedermann B L: Urinary
interleukin-6 and interleukin-8 in children with urinary tract
infection. Pediatr Nephrol 2000, 15(3-4):236-240. [0157] 36. Ko Y
C, Mukaida N, lshiyama S, Tokue A, Kawai T, Matsushima K, Kasahara
T: Elevated interleukin-8 levels in the urine of patients with
urinary tract infections. Infect Immun 1993, 61(4):1307-1314.
PMCID: 281363 [0158] 37. Rodhe N, Lofgren S, Strindhall J, Matussek
A, Molstad S: Cytokines in urine in elderly subjects with acute
cystitis and asymptomatic bacteriuria. Scand J Prim Health Care
2009, 27(2):74-79. PMCID: 3410465 [0159] 38. Joensson H N, Samuels
M L, Brouzes E R, Medkova M, Uhlen M, Link D R, Andersson-Svahn H:
Detection and analysis of low-abundance cell-surface biomarkers
using enzymatic amplification in microfluidic droplets. Angew Chem
Int Ed Engl 2009, 48(14):2518-2521. [0160] 39. Song H, Chen D L,
Ismagilov R F: Reactions in droplets in microfluidic channels.
Angew Chem Int Ed Engl 2006, 45(44):7336-7356. PMCID: 1766322
[0161] 40. Agresti J J, Antipov E, Abate A R, Ahn K, Rowat AC,
Baret J C, Marquez M, Klibanov A M, Griffiths A D, Weitz D A:
Ultrahigh-throughput screening in drop-based microfluidics for
directed evolution. Proc Natl Acad Sci USA 2010, 107(9):4004-4009.
PMCID: 2840095 [0162] 41. Kiss M M, Ortoleva-Donnelly L, Beer N R,
Warner J, Bailey C G, Colston B W, Rothberg J M, Link D R, Leamon J
H: High-throughput quantitative polymerase chain reaction in
picoliter droplets. Anal Chem 2008, 80(23):8975-8981. PMCID:
2771884 [0163] 42. Koster S, Angile F E, Duan H, Agresti J J,
Wintner A, Schmitz C, Rowat A C, Merten C A, Pisignano D, Griffiths
A D, Weitz D A: Drop-based microfluidic devices for encapsulation
of single cells. Lab Chip 2008, 8(7):1110-1115. [0164] 43. Brouzes
E, Medkova M, Savenelli N, Marran D, Twardowski M, Hutchison J B,
Rothberg J M, Link D R, Perrimon N, Samuels M L: Droplet
microfluidic technology for single-cell high-throughput screening.
Proc Natl Acad Sci USA 2009, 106(34):14195-14200. PMCID: 2732882
[0165] 44. Mazutis L, Araghi A F, Miller O J, Baret J C, Frenz L,
Janoshazi A, Taly V, Miller B J, Hutchison J B, Link D, Griffiths A
D, Ryckelynck M: Droplet-based microfluidic systems for
high-throughput single DNA molecule isothermal amplification and
analysis. Anal Chem 2009, 81(12):4813-4821. [0166] 45. Shum H C,
Kim J W, Weitz D A: Microfluidic fabrication of monodisperse
biocompatible and biodegradable polymersomes with controlled
permeability. J Am Chem Soc 2008, 130(29):9543-9549. [0167] 46.
Golberg A, Linshiz G, Kravets I, Stawski N, Hillson N J, Yarmush M
L, Marks R S, Konry T: Cloud-Enabled Microscopy and Droplet
Microfluidic Platform for Specific Detection of Escherichia coli in
Water. PLoS One 2014, 9(1):e86341. PMCID: 3903517. See also
PCT/US2014/010412. [0168] 47. Konry T, Golberg A, Yarmush M: Live
single cell functional phenotyping in droplet nano-liter reactors.
Sci Rep 2013, 3:3179. PMCID: 3822379 [0169] 48. Konry T, Lerner A,
Yarmush M L, Smolina I: Target DNA detection and quantitation on a
single cell with single base resolution. Technology 2013, 88(1).
[0170] 49. Konry T, Bale S S, Bhushan A, Shen K, Seker E, Polyak B,
Yarmush M: Particles and microfluidics merged: perspectives of
highly sensitive diagnostic detection. Mikrochim Acta 2012,
176(3-4):251-269. PMCID: 4219152 [0171] 50. Konry T, Walt D R:
Intelligent medical diagnostics via molecular logic. J Am Chem Soc
2009, 131(37):13232-13233. PMCI D: 2750850 [0172] 51. Konry T,
Hayman R B, Walt D R: Microsphere-based rolling circle
amplification microarray for the detection of DNA and proteins in a
single assay. Anal Chem 2009, 81(14):5777-5782. PMCID: 2730947
[0173] 52. Konry T, Dominguez-Villar M, Baecher-Allan C, Hafler D
A, Yarmush M L: Droplet-based microfluidic platforms for single T
cell secretion analysis of IL-10 cytokine. Biosens Bioelectron
2011, 26(5):2707-2710. PMCI D: 3141325 [0174] 53. LaFratta C N,
Walt D R: Very high density sensing arrays. Chem Rev 2008,
108(2):614-637. [0175] 54. Gorris H H, Blicharz T M, Walt D R:
Optical-fiber bundles. Febs J 2007, 274(21):5462-5470. [0176] 55.
Di Padova F E, Brade H, Barclay G R, Poxton I R, Liehl E, Schuetze
E, Kocher H P, Ramsay G, Schreier M H, McClelland D B, et al.: A
broadly cross-protective monoclonal antibody binding to Escherichia
coli and Salmonella lipopolysaccharides. Infect Immun 1993,
61(9):3863-3872. PMCID: 281087 [0177] 56. Kuhn H M, Meier-Dieter U,
Mayer H: ECA, the enterobacterial common antigen. FEMS Microbiol
Rev 1988, 4(3):195-222. [0178] 57. Brade L, Podschun R, Brade H: A
monoclonal antibody with specificity for the genus Klebsiella binds
to a common epitope located in the core region of Klebsiella
lipopolysaccharide. J Endotoxin Res 2001, 7(2):119-124. [0179] 58.
DiGiandomenico A, Warrener P, Hamilton M, Guillard S, Ravn P,
Minter R, Camara M M, Venkatraman V, Macgill R S, Lin J, Wang Q,
Keller A E, Bonnell J C, Tomich M, Jermutus L, McCarthy M P,
Melnick D A, Suzich J A, Stover C K: Identification of broadly
protective human antibodies to Pseudomonas aeruginosa
exopolysaccharide Psi by phenotypic screening. J Exp Med 2012,
209(7):1273-1287. PMCID: 3405507 [0180] 59. Juskowiak B: Nucleic
acid-based fluorescent probes and their analytical potential. Anal
Bioanal Chem 2011, 399(9):3157-3176. PMCID: 3044240 [0181] 60.
Frickmann H, Essig A, Hagen R M, Riecker M, Jerke K, Ellison D,
Poppert S: Rapid identification of Acinetobacter spp. by
fluorescence in situ hybridization (FISH) from colony and blood
culture material. Eur J Microbiol Immunol (Bp) 2011, 1(4):289-296.
PMCID: 3918131 [0182] 61. Priya N G, Pandey N, Rajagopal R: LNA
probes substantially improve the detection of bacterial
endosymbionts in whole mount of insects by fluorescent in-situ
hybridization. BMC Microbiol 2012, 12:81. PMCID: 3536699 [0183] 62.
Kubota K, Ohashi A, Imachi H, Harada H: Improved in situ
hybridization efficiency with locked-nucleic-acid-incorporated DNA
probes. Appl Environ Microbiol 2006, 72(8):5311-5317. PMCID:
1538721 [0184] 63. Chiaraviglio L, Kirby J E: Evaluation of
impermeant, DNA-binding dye fluorescence as a real-time readout of
eukaryotic cell toxicity in a high throughput screening format.
Assay Drug Dev Technol 2014, 12(4):219-228. PMCID: 4026211
[0185] 64. Burnham C A, Frobel R A, Herrera M L, Wickes B L: Rapid
ertapenem susceptibility testing and Klebsiella pneumoniae
carbapenemase phenotype detection in Klebsiella pneumoniae isolates
by use of automated microscopy of immobilized live bacterial cells.
Journal of clinical microbiology 2014, 52(3):982-986. PMCID:
3957783 [0186] 65. Albers A C, Fletcher R D: Accuracy of
calibrated-loop transfer. Journal of clinical microbiology 1983,
18(1):40-42. PMCID: 270741 [0187] 66.
www.fda.gov/ohrms/dockets/98fr/000109gd.pdf [0188] 67. Wu H,
Wheeler A, Zare R N (2004) Chemical cytometry on a picoliter-scale
integrated microfluidic chip. Proc Natl Acad Sci USA
101(35):12809-13. [0189] 68. Taff B M, Voldman J (2005) A scalable
addressable positive-dielectrophoretic cell-sorting array. Anal
Chem 77(24):7976-83. [0190] 69. Jaeger M S, Uhlig K, Schnelle T,
and Mueller T (2008) Contact-free single-cell cultivation by
negative dielectrophoresis. J. Phys. D: Appl. Phys. 41, 175502.
[0191] 70. Werner M, Palankar R, Arm L, Hovius R, Vogel H (2015)
Microfluidic Single-Cell Analysis with Affinity Beads. Small doi:
10.1002/sm11.201402650. [0192] 71. Rettig J R, Folch A (2005)
Large-scale single-cell trapping and imaging using microwell
arrays. Anal Chem 77(17):5628-34. [0193] 72. Han Q, Bagheri N,
Bradshaw E M, Hafler D A, Lauffenburger D A, et al. (2012)
Polyfunctional responses by human T cells result from sequential
release of cytokines. Proc Natl Acad Sci USA. 109(5):1607-12.
[0194] 73. Faley S, Seale K, Hughey J, Schaffer D K, VanCompernolle
S, et al. (2008) Microfluidic platform for real-time signaling
analysis of multiple single T cells in parallel. Lab Chip
8(10):1700-12. [0195] 74. Chung K, Rivet C A, Kemp M L, Lu H (2011)
Imaging single-cell signaling dynamics with a deterministic
high-density single-cell trap array. Anal Chem 83(18):7044-52.
[0196] 75. Chung J, Kim Y J, Yoon E (2011) Highly-efficient
single-cell capture in microfluidic array chips using differential
hydrodynamic guiding structures. Appl Phys Lett 98(12):123701.
[0197] 76. Jin D, Deng B, Li J X, Cai W, Tu L, et al. (2015) A
microfluidic device enabling high-efficiency single cell trapping.
Biomicrofluidics 9(1):014101. [0198] 77. Zhang K, Chou C K, Xia X,
Hung M C, Qin L (2014) Block-Cell-Printing for live single-cell
printing. Proc Natl Acad Sci USA 111(8):2948-53. [0199] 78. Di
Carlo D, Wu L Y, Lee L P (2006) Dynamic single cell culture array.
Lab Chip. 6(11):1445-9. [0200] 79. Kobel S, Valero A, Latt J,
Renaud P, Lutolf M (2010) Optimization of microfluidic single cell
trapping for long-term on-chip culture. Lab Chip 10(7):857-63
[0201] 80. Skelley A M, Kirak O, Suh H, Jaenisch R, Voldman J
(2009) Microfluidic control of cell pairing and fusion. Nat Methods
6(2):147-52.
[0202] As used herein, "consisting essentially of" allows the
inclusion of materials or steps that do not materially affect the
basic and novel characteristics of the claim. Any recitation herein
of the term "comprising", particularly in a description of
components of a composition or in a description of elements of a
device, can be exchanged with "consisting essentially of" or
"consisting of".
[0203] While the present invention has been described in
conjunction with certain preferred embodiments, one of ordinary
skill, after reading the foregoing specification, will be able to
effect various changes, substitutions of equivalents, and other
alterations to the compositions and methods set forth herein.
* * * * *
References